Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription Articles published in Hepatology Retrieve available abstracts of 597 articles: HTML format

Single Articles

November 2025
1. JIANG Y, Li Y, Wu T, Cao L, et al
   GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses.
   Hepatology. 2025 Nov 7. doi: 10.1097/HEP.0000000000001605.
   PubMed     Abstract available
   
   
   
2. HUA H, Wang D, He L, Chen N, et al
   KLF9 drives intermittent hypoxia-induced NAFLD by suppressing the NR4A1-p38 MAPK hepatic metabolic axis.
   Hepatology. 2025 Nov 4. doi: 10.1097/HEP.0000000000001606.
   PubMed     Abstract available
   
   
   
3. LEI Z, Wu Y, Xue W, Zhu D, et al
   Epigenetic repression of hepatocyte FoxO1 disrupts local immune homeostasis and promotes liver inflammation.
   Hepatology. 2025 Nov 4. doi: 10.1097/HEP.0000000000001590.
   PubMed     Abstract available
   
   
   
4. HARTMANN P, Mouzaki M, Hassan S, Kehar M, et al
   Call to action-Pediatric MASLD requires immediate attention to curb health crisis.
   Hepatology. 2025;82:1341-1351.
   PubMed     Abstract available
   
   
   
5. WANG L, Dong W, Fan L, Kong H, et al
   Repression of the ERRgamma-CYP2E1 pathway by FGF4 mitigates alcohol-associated liver injury.
   Hepatology. 2025;82:1138-1154.
   PubMed     Abstract available
   
   
   
6. SERPER M, Tang H, Zhang S, McCullough A, et al
   Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study.
   Hepatology. 2025;82:1187-1197.
   PubMed     Abstract available
   
   
   
7. ROUSSEAU D, Bonnafous S, Soysouvanh F, Sarrail D, et al
   CD44 in myeloid cells is a major driver of liver inflammation and injury in alcohol-associated liver disease.
   Hepatology. 2025;82:1211-1228.
   PubMed     Abstract available
   
   
   
8. NEWTON KP, Jayasekera D, Blackford AL, Behling C, et al
   Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes.
   Hepatology. 2025;82:1198-1210.
   PubMed     Abstract available
   
   
   
9. UNALP-ARIDA A, Ruhl CE
   Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data.
   Hepatology. 2025;82:1256-1273.
   PubMed     Abstract available
   
   
   
10. NOUREDDIN M
    MASH clinical trials and drugs pipeline: An impending tsunami.
    Hepatology. 2025;82:1325-1340.
    PubMed     Abstract available
    
    
    
11. WANG X, Zhang L, Dong B
    Molecular mechanisms in MASLD/MASH-related HCC.
    Hepatology. 2025;82:1303-1324.
    PubMed     Abstract available
    
    
    
12. KHALID MB, Ilyas SI
    Surgical resection for hepatocellular carcinoma: Leave no TACE?
    Hepatology. 2025;82:1039-1040.
    PubMed    
    
    
    October 2025
13. WEI T, Ma ZJ, Guo S, Weiss M, et al
    Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling.
    Hepatology. 2025 Oct 30. doi: 10.1097/HEP.0000000000001594.
    PubMed     Abstract available
    
    
    
14. HAN J, Zhao Y, Zhao J
    Yttrium-90 superiority in hepatocellular carcinoma downstaging: Treatment effect or selection bias?
    Hepatology. 2025 Oct 28. doi: 10.1097/HEP.0000000000001579.
    PubMed    
    
    
    
15. WALIA N, Hui S, Braude M
    Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001586.
    PubMed    
    
    
    
16. GRIMAUD E, Gardin A, Ackermann O, Habes D, et al
    Serum bile acid levels predict the development of portal hypertension and high-risk esophageal varices following successful Kasai in biliary atresia.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001592.
    PubMed     Abstract available
    
    
    
17. DELGADO ER, Patel P, Tao J, Krutsenko Y, et al
    Glutamine synthetase loss in beta-catenin-mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001591.
    PubMed     Abstract available
    
    
    
18. JOHN BV, Bastaich D, Singal AG, Dahman B, et al
    Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD.
    Hepatology. 2025 Oct 20. doi: 10.1097/HEP.0000000000001587.
    PubMed    
    
    
    
19. PATIDAR KR, Sharma P
    Time to focus on POCUS For AKI management in cirrhosis.
    Hepatology. 2025 Oct 16. doi: 10.1097/HEP.0000000000001583.
    PubMed    
    
    
    
20. ZHANG X, Gong H, Gu K, Chen D, et al
    Letter to the Editor: Re-evaluating the clinical relevance of the RIPPLY1-TBX19 Axis in CTNNB1-Mutant hepatocellular carcinoma.
    Hepatology. 2025 Oct 14. doi: 10.1097/HEP.0000000000001572.
    PubMed    
    
    
    
21. SALLMON H, Laufer G, Kurath-Koller S, Kramer P, et al
    Letter to the editor: Esophageal varices in Fontan patients - circulatory or hepatic failure?
    Hepatology. 2025 Oct 13. doi: 10.1097/HEP.0000000000001573.
    PubMed    
    
    
    
22. ABAD-JORDA L, Andres-Rozas M, Martinez-Alcocer A, Aspas J, et al
    Hepatocyte-derived extracellular vesicles promote endothelial dedifferentiation in chronic liver disease through the miR-153-3p - pyroptosis axis.
    Hepatology. 2025 Oct 10. doi: 10.1097/HEP.0000000000001567.
    PubMed     Abstract available
    
    
    
23. MA H, Zhang VX, Tsui YM, Lee JM, et al
    Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma.
    Hepatology. 2025 Oct 9. doi: 10.1097/HEP.0000000000001561.
    PubMed     Abstract available
    
    
    
24. HUANG X, Lisman T
    Cirrhotic portal vein thrombosis as a vascular rather than a thrombotic disorder.
    Hepatology. 2025 Oct 8. doi: 10.1097/HEP.0000000000001565.
    PubMed    
    
    
    
25. ANTON A, Shalaby S, Botero ML, Blasi A, et al
    Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis.
    Hepatology. 2025 Oct 6. doi: 10.1097/HEP.0000000000001547.
    PubMed     Abstract available
    
    
    
26. FOERSTER F, Wiesmann L, Bark P, Galle PR, et al
    Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma.
    Hepatology. 2025 Oct 2. doi: 10.1097/HEP.0000000000001554.
    PubMed     Abstract available
    
    
    September 2025
27. WANG X, Luo J, Han L, Xu T, et al
    FXR splicing by SF3B3 promotes MYC-driven hepatocarcinogenesis.
    Hepatology. 2025 Sep 23. doi: 10.1097/HEP.0000000000001523.
    PubMed     Abstract available
    
    
    
28. PREMKUMAR M, Kajal K, Roy A, Izzy M, et al
    'Point-of-Care Ultrasound (POCUS) guided volume management and the effect of cirrhotic cardiomyopathy on acute kidney injury outcomes in cirrhosis'.
    Hepatology. 2025 Sep 23. doi: 10.1097/HEP.0000000000001524.
    PubMed     Abstract available
    
    
    
29. DELTENRE P, Marot A, Henrion J
    A prognostic model in patients with alcohol-related cirrhosis does exist.
    Hepatology. 2025 Sep 17. doi: 10.1097/HEP.0000000000001532.
    PubMed    
    
    
    
30. PAN Z
    Letter to the editor: Technical considerations in the development of a multimodal deep learning model for predicting hepatocellular carcinoma outcomes.
    Hepatology. 2025 Sep 17. doi: 10.1097/HEP.0000000000001534.
    PubMed    
    
    
    
31. LIU TH, Yang HC
    Letter to the Editor: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy.
    Hepatology. 2025 Sep 4. doi: 10.1097/HEP.0000000000001459.
    PubMed    
    
    
    
32. ZHANG L, Li H, Zong W, Li B, et al
    Letter to the Editor: Revisiting FOXP3 Expression and its prognostic implications in hepatocellular carcinoma.
    Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001512.
    PubMed    
    
    
    
33. HUANG CH, Ku WT, Wu TH, Lin PT, et al
    Reply to the Letter to the Editor: Revisiting FOXP3 expression and its prognostic implications in hepatocellular carcinoma.
    Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001515.
    PubMed    
    
    
    
34. LAI JC, Tapper E, Tandon P
    Integrative hepatology: Enhancing overall health to manage liver disease.
    Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001516.
    PubMed     Abstract available
    
    
    
35. JEONG JM, Choi SE, Shim YR, Kim HH, et al
    CX3CR1+ macrophages interact with HSCs to promote HCC through CD8+ T-cell suppression.
    Hepatology. 2025;82:655-668.
    PubMed     Abstract available
    
    
    
36. LI W, Chi Y, Xiao X, Li J, et al
    Plasma FSTL-1 as a noninvasive diagnostic biomarker for patients with advanced liver fibrosis.
    Hepatology. 2025;82:669-682.
    PubMed     Abstract available
    
    
    
37. YANG Y, Ni Q, Li H, Sun J, et al
    Genomic and the tumor microenvironment heterogeneity in multifocal hepatocellular carcinoma.
    Hepatology. 2025;82:582-598.
    PubMed     Abstract available
    
    
    
38. ZHOU KQ, Zhong YC, Song MF, Sun YF, et al
    Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution.
    Hepatology. 2025;82:566-581.
    PubMed     Abstract available
    
    
    
39. SINGAL AG, Quirk L, Boike J, Chernyak V, et al
    Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel.
    Hepatology. 2025;82:794-809.
    PubMed     Abstract available
    
    
    
40. PANG Z, Zhang H, Zheng S, Yang X, et al
    HNF4alpha-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation.
    Hepatology. 2025;82:702-721.
    PubMed     Abstract available
    
    
    
41. FACCIOLI LAP, Sun Y, Animasahun O, Motomura T, et al
    Human-induced pluripotent stem cell-based hepatic modeling of lipid metabolism-associated TM6SF2-E167K variant.
    Hepatology. 2025;82:638-654.
    PubMed     Abstract available
    
    
    
42. ERICKSON H
    Hepatic stellate cells and macrophages: Key players in HCC immune suppression.
    Hepatology. 2025;82:545-546.
    PubMed    
    
    
    
43. WILECHANSKY RM
    Surging sludge: Intrahepatic cholangiocarcinoma mortality on the rise worldwide.
    Hepatology. 2025;82:543-544.
    PubMed    
    
    
    
44. ZHANGYUAN G, Yu W, Tian W, Xie J, et al
    RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1-mutated hepatocellular carcinoma.
    Hepatology. 2025 Sep 1. doi: 10.1097/HEP.0000000000001483.
    PubMed     Abstract available
    
    
    
45. SUN Y, Chen S, Xu X, Piao H, et al
    Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis.
    Hepatology. 2025 Sep 1. doi: 10.1097/HEP.0000000000001504.
    PubMed     Abstract available
    
    
    August 2025
46. HILSCHER MB
    The pressure is on: Elucidating hemodynamic profiles associated with esophageal varices in the Fontan circulation.
    Hepatology. 2025 Aug 26. doi: 10.1097/HEP.0000000000001510.
    PubMed    
    
    
    
47. ANANIA FA, Hager R, Higgins K, Makar GA, et al
    Non-Invasive Tests: Establishing efficacy for metabolic dysfunction associated steatohepatitis beyond the biopsy-current perspectives from the division of hepatology and nutrition, US Food and Drug Administration.
    Hepatology. 2025 Aug 26. doi: 10.1097/HEP.0000000000001509.
    PubMed     Abstract available
    
    
    
48. DING J, She HY, Cheng Y, Sun HY, et al
    A novel mechanism involving USP53-regulated BSEP trafficking underlies low-GGT intrahepatic cholestasis.
    Hepatology. 2025 Aug 19. doi: 10.1097/HEP.0000000000001501.
    PubMed     Abstract available
    
    
    
49. ZHOU SL, Yin D, Hu ZQ, Luo CB, et al
    Erratum: A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls hepatocellular carcinoma progression.
    Hepatology. 2025 Aug 14. doi: 10.1097/HEP.0000000000001476.
    PubMed    
    
    
    
50. JOHN BV, Bastaich DR, Deng Y, Singal AG, et al
    Use of liver stiffness measurement for hepatocellular carcinoma risk stratification in metabolic dysfunction associated steatotic liver disease.
    Hepatology. 2025 Aug 14. doi: 10.1097/HEP.0000000000001498.
    PubMed     Abstract available
    
    
    
51. INDRE MG, Leucuta DC, Lupsor-Platon M, Turco L, et al
    Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multilevel random effects model meta-analysis.
    Hepatology. 2025;82:454-469.
    PubMed     Abstract available
    
    
    
52. LOH JJ, Ng KY, Huang IB, Deng M, et al
    DGKH-mediated phosphatidic acid oncometabolism as a driver of self-renewal and therapy resistance in HCC.
    Hepatology. 2025;82:308-325.
    PubMed     Abstract available
    
    
    
53. DRIESSEN S, Francque SM, Anker SD, Castro Cabezas M, et al
    Metabolic dysfunction-associated steatotic liver disease and the heart.
    Hepatology. 2025;82:487-503.
    PubMed     Abstract available
    
    
    
54. SU T, Huang M, Liao J, Lin S, et al
    Erratum: Insufficient radiofrequency ablation promotes hepatocellular carcinoma metastasis through N6-methyladenosine mRNA methylation-dependent mechanism.
    Hepatology. 2025;82:E35-E36.
    PubMed    
    
    
    July 2025
55. ACUNA-PILARTE K, Reichert EC, Green YS, Halberg LM, et al
    Erratum: HAF prevents hepatocyte apoptosis and progression to MASH and HCC through transcriptional regulation of the NF-kappaB pathway.
    Hepatology. 2025 Jul 30. doi: 10.1097/HEP.0000000000001416.
    PubMed    
    
    
    
56. FAN G, Han X, Shi Y
    Reply: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
    Hepatology. 2025 Jul 30. doi: 10.1097/HEP.0000000000001480.
    PubMed    
    
    
    
57. TAKEFUJI Y
    Letter to the editor: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
    Hepatology. 2025 Jul 29. doi: 10.1097/HEP.0000000000001479.
    PubMed    
    
    
    
58. APODAKA-BIGURI M, Simao AL, Gonzalez-Romero F, Mestre D, et al
    E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p.
    Hepatology. 2025 Jul 28. doi: 10.1097/HEP.0000000000001461.
    PubMed     Abstract available
    
    
    
59. NAKIB D, MacParland S
    Decoding the PSC fibrotic niche: Hepatocyte stress and metallothioneins.
    Hepatology. 2025 Jul 25. doi: 10.1097/HEP.0000000000001478.
    PubMed    
    
    
    
60. HUANG Q, Wang W, Ge Q, Xu D, et al
    NEK7 induced phosphorylation of EGFR on serine 1070 drive the acquired lenvatinib resistance in hepatocellular carcinoma.
    Hepatology. 2025 Jul 22. doi: 10.1097/HEP.0000000000001474.
    PubMed     Abstract available
    
    
    
61. SEIF EL DAHAN K, Daher D, Rich NE, Nayak AJ, et al
    Causes of mortality among patients with early-stage hepatocellular carcinoma.
    Hepatology. 2025 Jul 22. doi: 10.1097/HEP.0000000000001471.
    PubMed     Abstract available
    
    
    
62. TELLEZ L, Toledano M, Alvarez M, Garrido-Lestache E, et al
    Distinctive hemodynamic phenotype in Fontan-type circulation patients with distal esophageal varices.
    Hepatology. 2025 Jul 22. doi: 10.1097/HEP.0000000000001472.
    PubMed     Abstract available
    
    
    
63. ABRUZZESE GA, Martinez-Chantar ML
    Minor players, major signals: Unveiling the systemic and gut-localized impact of microbial amidated bile acids in hepatopancreatobiliary disease.
    Hepatology. 2025 Jul 21. doi: 10.1097/HEP.0000000000001473.
    PubMed    
    
    
    
64. BAJAJ JS, Reddy KR, Tandon P, Lai JC, et al
    Salivary microbiome and serum metabolomics add to clinical biomarkers to predict 6-month hospitalizations in a multi-center cirrhosis outpatient cohort.
    Hepatology. 2025 Jul 9. doi: 10.1097/HEP.0000000000001462.
    PubMed     Abstract available
    
    
    
65. SCHEINER B, Pinter M
    Reply: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy.
    Hepatology. 2025 Jul 7. doi: 10.1097/HEP.0000000000001460.
    PubMed    
    
    
    
66. SU TH, Shin EC
    Peripheral blood Foxp3-High tregs: A novel prognostic biomarker in hepatocellular carcinoma.
    Hepatology. 2025 Jul 7. doi: 10.1097/HEP.0000000000001464.
    PubMed    
    
    
    
67. SINHA S, Ali Q, Zhang T, T-Nguyen DH, et al
    Aging disrupts hepatocyte zonation homeostasis in mice and humans.
    Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001451.
    PubMed     Abstract available
    
    
    
68. GUO Y, Zhang Q, Li B, Dai W, et al
    Biliary YB-1/GLI2 axis facilitates ductular reaction and promotes hepatic stellate cell activation via SPP1/Integrin alphavbeta1 signaling during liver fibrogenesis.
    Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001458.
    PubMed     Abstract available
    
    
    
69. CHONG LUGON N, Rabiee A, Mezzacappa C, Kaplan DE, et al
    Prognostic significance of mild ascites in patients with cirrhosis.
    Hepatology. 2025 Jul 3. doi: 10.1097/HEP.0000000000001452.
    PubMed     Abstract available
    
    
    
70. TRAUNER M, Karpen SJ, Dawson PA
    Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease.
    Hepatology. 2025 Jul 2. doi: 10.1097/HEP.0000000000001438.
    PubMed     Abstract available
    
    
    
71. UNTALAN M, A Crimmins N, Yates KP, A Mencin A, et al
    Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction-associated steatotic liver disease: An observational study.
    Hepatology. 2025;82:155-164.
    PubMed     Abstract available
    
    
    
72. SALIBA-GUSTAFSSON P, Justesen JM, Ranta A, Sharma D, et al
    A functional genomic framework to elucidate novel causal metabolic dysfunction-associated fatty liver disease genes.
    Hepatology. 2025;82:165-183.
    PubMed     Abstract available
    
    
    
73. HAI S, Li X, Xie E, Wu W, et al
    Intestinal IL-33 promotes microbiota-derived trimethylamine N -oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1alpha.
    Hepatology. 2025;82:184-198.
    PubMed     Abstract available
    
    
    
74. DIAZ LA, Winder GS, Leggio L, Bajaj JS, et al
    New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease.
    Hepatology. 2025;82:254-271.
    PubMed     Abstract available
    
    
    
75. ADLAT S, Vazquez Salgado AM, Lee M, Yin D, et al
    Emerging and potential use of CRISPR in human liver disease.
    Hepatology. 2025;82:232-253.
    PubMed     Abstract available
    
    
    
76. HUANG CH, Ku WT, Mahalingam J, Wu CH, et al
    Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in hepatocellular carcinoma.
    Hepatology. 2025 Jul 1. doi: 10.1097/HEP.0000000000001428.
    PubMed     Abstract available
    
    
    
77. XU X, Li H, Lin H, Li Q, et al
    MIF-mediated crosstalk between THRSP+ hepatocytes and CD74+ lipid-associated macrophages in hepatic periportal zone drives MASH.
    Hepatology. 2025 Jul 1. doi: 10.1097/HEP.0000000000001429.
    PubMed     Abstract available
    
    
    June 2025
78. NAM H, Kim DY, Kim DY, Kim JH, et al
    Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab.
    Hepatology. 2025 Jun 30. doi: 10.1097/HEP.0000000000001444.
    PubMed     Abstract available
    
    
    
79. ZHANG L, Han C, Shrestha MM, Le J, et al
    The OGT-TFF2 axis mediates intrahepatic crosstalk and MASH pathogenesis.
    Hepatology. 2025 Jun 30. doi: 10.1097/HEP.0000000000001445.
    PubMed     Abstract available
    
    
    
80. XIAOFANG S, Zhanhui O, Ruochan C, Xiaohua N, et al
    Erratum: Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001384.
    PubMed    
    
    
    
81. LI J, Xu L, Rui F, Tran S, et al
    Type 2 Diabetes mellitus as an independent predictor of significant fibrosis in treatment-naive chronic hepatitis B patients with concurrent hepatic steatosis.
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001442.
    PubMed     Abstract available
    
    
    
82. YANG DL, Ye L, Zeng FJ, Liu J, et al
    Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001401.
    PubMed    
    
    
    
83. TEMPRANO AG, Romero MR, Ghallab A, Llera L, et al
    Gut-to-Bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders.
    Hepatology. 2025 Jun 23. doi: 10.1097/HEP.0000000000001441.
    PubMed     Abstract available
    
    
    
84. TAO J, Wang J
    Reply: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function.
    Hepatology. 2025 Jun 18. doi: 10.1097/HEP.0000000000001435.
    PubMed    
    
    
    
85. NI J, Zhai D, Li J, Li B, et al
    Letter to editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function.
    Hepatology. 2025 Jun 16. doi: 10.1097/HEP.0000000000001434.
    PubMed    
    
    
    
86. SU JY, Li JR, Pan LX, Ma YL, et al
    Tertiary lymphoid structures in hepatocellular carcinoma: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy.
    Hepatology. 2025 Jun 11. doi: 10.1097/HEP.0000000000001433.
    PubMed     Abstract available
    
    
    
87. SHAW J, Acharya C, Fagan A, Olofson A, et al
    Health IT interventions reduce avoidable readmissions in cirrhosis: The HEROIC randomized controlled trial.
    Hepatology. 2025 Jun 11. doi: 10.1097/HEP.0000000000001424.
    PubMed     Abstract available
    
    
    
88. LI F, Li Y, Wang L, Xu L, et al
    Tumor microenvironment heterogeneity and progression mechanisms in intrahepatic cholangiocarcinoma: A study based on single-cell and spatial transcriptomic sequencing.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001423.
    PubMed     Abstract available
    
    
    
89. PEDDU DK, Tedesco N, Rutledge SM, Wijarnpreecha K, et al
    Social determinants of health influence the risk of cirrhosis: A diverse nationwide cohort study.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001420.
    PubMed     Abstract available
    
    
    
90. BIAN Q, Wang S, Song Z, Liu F, et al
    Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001422.
    PubMed     Abstract available
    
    
    
91. WANG H, Wang S, Lei Y, Chen Y, et al
    Serum amyloid A1-Induced intrahepatic regulatory T cell dysfunction drives autoimmune hepatitis progression.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001419.
    PubMed     Abstract available
    
    
    
92. MANDORFER M, Jachs M, Semmler G
    Roadmap for a generally accepted model to predict first hepatic decompensation in compensated advanced chronic liver disease.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001431.
    PubMed    
    
    
    
93. LIANG BG, Zheng YM, Xu MH, Gao C, et al
    The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in hepatocellular carcinoma.
    Hepatology. 2025 Jun 2. doi: 10.1097/HEP.0000000000001392.
    PubMed     Abstract available
    
    
    
94. TINCOPA MA, Diaz LA, Huang DQ, Arab JP, et al
    Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2025;81:1792-1804.
    PubMed     Abstract available
    
    
    
95. MARINO Z, Garcia-Sola C, Rios J, Bono A, et al
    Exchangeable copper for patients with Wilson disease at follow-up: Rethinking normal ranges or changing methodology.
    Hepatology. 2025;81:1728-1739.
    PubMed     Abstract available
    
    
    
96. FAN L, Tian C, Yang W, Liu X, et al
    HKDC1 promotes liver cancer stemness under hypoxia through stabilizing beta-catenin.
    Hepatology. 2025;81:1685-1699.
    PubMed     Abstract available
    
    
    
97. BAKRANIA A, Mo Y, Zheng G, Bhat M, et al
    RNA nanomedicine in liver diseases.
    Hepatology. 2025;81:1847-1877.
    PubMed     Abstract available
    
    
    
98. MACHIDA K, Tsukamoto H, Liu JC, Han YP, et al
    Retraction: C-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2025;81:E181.
    PubMed    
    
    
    
99. JIANG JX, Fish SR, Tomilov A, Li Y, et al
    Erratum: Nonphagocytic activation of NOX2 is implicated in progressive nonalcoholic steatohepatitis during aging.
    Hepatology. 2025;81:E180.
    PubMed    
    
    
    
100. HARRIS K
     LPCN 1148: Rebuilding muscle memory in cirrhosis patients.
     Hepatology. 2025;81:1625-1626.
     PubMed    
     
     
     
101. EISWERTH M, Arab JP
     A new voice in diagnosing and predicting hepatic encephalopathy.
     Hepatology. 2025;81:1623-1624.
     PubMed    
     
     
     May 2025
102. NGUYEN T, Shin Y, Ruppa A, Krall AS, et al
     Galectin-1 modulates glycolysis via a GM1-galactose-dependent pathway to promote hyperthermia resistance in hepatocellular carcinoma.
     Hepatology. 2025 May 21. doi: 10.1097/HEP.0000000000001391.
     PubMed     Abstract available
     
     
     
103. XIE L, Chen H, Zhang L, Yang YY, et al
     Suppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in hepatic stellate cells.
     Hepatology. 2025 May 19. doi: 10.1097/HEP.0000000000001405.
     PubMed     Abstract available
     
     
     
104. REGHUPATY SC, Raha S, Mendoza R, Manna D, et al
     TATA-box binding protein associated factor 2 (TAF2) in hepatocyte survival and tumorigenesis.
     Hepatology. 2025 May 19. doi: 10.1097/HEP.0000000000001406.
     PubMed     Abstract available
     
     
     
105. LAU G, Sangro B, Cheng AL, Kudo M, et al
     Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial.
     Hepatology. 2025 May 16. doi: 10.1097/HEP.0000000000001385.
     PubMed     Abstract available
     
     
     
106. JIN Y, Wang M, Xu A, Xu B, et al
     Letter to the Editor: Association between mean arterial pressure and terlipressin in the reversal of hepatorenal syndrome-acute kidney injury.
     Hepatology. 2025 May 15. doi: 10.1097/HEP.0000000000001404.
     PubMed    
     
     
     
107. WANG Y, Yang L, Li M, Hao J, et al
     Proenkephalin produced by neonatal T-bet+ Treg cells promotes periportal hepatocyte maturation.
     Hepatology. 2025 May 12. doi: 10.1097/HEP.0000000000001389.
     PubMed     Abstract available
     
     
     
108. WANG C, Dong D, Zhao N, Zhao S, et al
     Hepatocyte-specific C-C motif chemokine ligand 9 signaling promotes liver fibrosis progression in mice.
     Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001393.
     PubMed     Abstract available
     
     
     
109. YANG DL, Li YF, Li YJ, Qiu GG, et al
     Reply: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.
     Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001395.
     PubMed    
     
     
     
110. YU TC, Zhao L, Sze KM, Tian L, et al
     GPD1L supports glycerol-3-phosphate and triacylglycerol synthesis and promotes tumor progression in hepatocellular carcinoma.
     Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001394.
     PubMed     Abstract available
     
     
     
111. GENG Y, Schwabe RF
     Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications.
     Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001386.
     PubMed     Abstract available
     
     
     
112. O'ROURKE CJ, Andersen JB
     Intrahepatic Cholangiocarcinoma PANoptosidy.
     Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001398.
     PubMed    
     
     
     
113. WANG D, Yi S, Liu X
     Letter to the editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.
     Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001390.
     PubMed    
     
     
     
114. YANG Z, Jiang Y, Ma J, Wang L, et al
     LncRNA H19 promoted alcohol-associated liver disease through dysregulation of alternative splicing and methionine metabolism.
     Hepatology. 2025;81:1485-1500.
     PubMed     Abstract available
     
     
     
115. SUN Y, Wei H, Yu W, Gao H, et al
     The actin-binding protein drebrin disrupts NF2-LATS kinases complex assembly to facilitate liver tumorigenesis.
     Hepatology. 2025;81:1433-1451.
     PubMed     Abstract available
     
     
     
116. ZHANG S, Yan Y, Zeng XF, Gu Y, et al
     Associations of the EAT-Lancet reference diet with metabolic dysfunction-associated steatotic liver disease and its severity: A multicohort study.
     Hepatology. 2025;81:1583-1594.
     PubMed     Abstract available
     
     
     
117. HUANG DQ, Wilson LA, Behling C, Amangurbanova M, et al
     Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study.
     Hepatology. 2025;81:1553-1563.
     PubMed     Abstract available
     
     
     
118. OLUBAMIWA AO, Liao TJ, Zhao J, Dehanne P, et al
     Drug interaction with UDP-Glucuronosyltransferase (UGT) enzymes is a predictor of drug-induced liver injury.
     Hepatology. 2025;81:1512-1521.
     PubMed     Abstract available
     
     
     
119. MONIAUX N, Geoffre N, Deshayes A, Dos Santos A, et al
     Tumor suppressive role of the antimicrobial lectin REG3A targeting the O -GlcNAc glycosylation pathway.
     Hepatology. 2025;81:1416-1432.
     PubMed     Abstract available
     
     
     
120. NOVOA E, da Silva Lima N, Gonzalez-Rellan MJ, Chantada-Vazquez MDP, et al
     Mitochondrial antiviral signaling protein enhances MASLD progression through the ERK/TNFalpha/NFkappabeta pathway.
     Hepatology. 2025;81:1535-1552.
     PubMed     Abstract available
     
     
     
121. DE RUDDER M, Manco R, Coubeau L, Fontaine A, et al
     Vascular damage and excessive proliferation compromise liver function after extended hepatectomy in mice.
     Hepatology. 2025;81:1468-1484.
     PubMed     Abstract available
     
     
     
122. NORDEN-KRICHMAR TM, Rotroff D, Schwantes-An TH, Bataller R, et al
     Genomic approaches to explore susceptibility and pathogenesis of alcohol use disorder and alcohol-associated liver disease.
     Hepatology. 2025;81:1595-1606.
     PubMed     Abstract available
     
     
     
123. CHAGANTI J, Zeng G, Patil A, Lockart I, et al
     Altered blood-brain barrier permeability is associated with abnormal distant connectivity and regional homogeneity in covert hepatic encephalopathy - a cross sectional study.
     Hepatology. 2025 May 1. doi: 10.1097/HEP.0000000000001343.
     PubMed     Abstract available
     
     
     
124. ZHANG Q, Song Q, Liu Y, Li J, et al
     Letter to the Editor: Redefining post-resection care: Critical analysis of adjuvant TACE in curative hepatocellular carcinoma management.
     Hepatology. 2025 May 1. doi: 10.1097/HEP.0000000000001327.
     PubMed    
     
     
     April 2025
125. YAO J, Liu P, Teng X, Kong D, et al
     Alcohol-induced disruption of hepatic m6A modification exacerbates alcohol-associated steatohepatitis by impairing liver immune microenvironment homeostasis.
     Hepatology. 2025 Apr 30. doi: 10.1097/HEP.0000000000001374.
     PubMed     Abstract available
     
     
     
126. FUJIWARA N, Matsushita Y, Tempaku M, Tachi Y, et al
     AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction-associated steatotic liver disease.
     Hepatology. 2025 Apr 22. doi: 10.1097/HEP.0000000000001360.
     PubMed     Abstract available
     
     
     
127. FIX OK, Kane M, Gainey CS, Khairat S, et al
     Privacy and fidelity: The promise of synthetic data in hepatology research.
     Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001361.
     PubMed    
     
     
     
128. WANG J, Zhang S, Fan T, Wu C, et al
     Letter to the Editor: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant phase.
     Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001365.
     PubMed    
     
     
     
129. HUI VW, Wong GL, Dai J, Tse YK, et al
     Increased risk of hepatocellular carcinoma in HBeAg-negative indeterminate phase compared to HBeAg-negative chronic infection.
     Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001354.
     PubMed     Abstract available
     
     
     
130. TSENG TC, Kao JH
     Reply: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant phase.
     Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001366.
     PubMed    
     
     
     
131. HOLMER M, Ingre M, Farkkila M, Ponsioen C, et al
     Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study.
     Hepatology. 2025 Apr 16. doi: 10.1097/HEP.0000000000001351.
     PubMed     Abstract available
     
     
     
132. YU Y, You Y, Duan Y, Kang M, et al
     Multiomics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma.
     Hepatology. 2025 Apr 15. doi: 10.1097/HEP.0000000000001352.
     PubMed     Abstract available
     
     
     
133. ROCCARINA D, Saltini D, Senzolo M, Nardelli S, et al
     Reply: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients.
     Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001350.
     PubMed    
     
     
     
134. TANTAI X, Li L, Dai S
     Letter to the editor: Considerations on the use of LPCN 1148 in cirrhotic patients with sarcopenia.
     Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001347.
     PubMed    
     
     
     
135. TANTAI X, Li L, Dai S
     Letter to the editor: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients.
     Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001349.
     PubMed    
     
     
     
136. BRUNO BJ, Weavil JC, Ogle J, Chidambaram N, et al
     Reply: Considerations on the use of LPCN 1148 in cirrhotic patients with sarcopenia.
     Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001348.
     PubMed    
     
     
     
137. YANG LX, Gao Q, Shi JY, Wang ZC, et al
     Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
     Hepatology. 2025 Apr 7. doi: 10.1097/HEP.0000000000001274.
     PubMed    
     
     
     
138. LAI JC, Lok AS
     Accurate prediction of hepatocellular carcinoma risk in patients with chronic HBV infection: HBeAg status and HBsAg level matter.
     Hepatology. 2025 Apr 3. doi: 10.1097/HEP.0000000000001345.
     PubMed    
     
     
     
139. WANG B, Hsu SH, Wang X, Kutay H, et al
     Erratum: Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: Role of E2F1 and transcription factor dimerization partner 2.
     Hepatology. 2025 Apr 3. doi: 10.1097/HEP.0000000000001261.
     PubMed    
     
     
     
140. NOBEL YR, Boike JR, Mazumder NR, Thornburg B, et al
     Predictors of long-term clinical outcomes after TIPS: An ALTA group study.
     Hepatology. 2025;81:1244-1255.
     PubMed     Abstract available
     
     
     
141. OJHA U, Kim S, Rhee CY, You J, et al
     Endothelial RUNX3 controls LSEC dysfunction and angiocrine LRG1 signaling to prevent liver fibrosis.
     Hepatology. 2025;81:1228-1243.
     PubMed     Abstract available
     
     
     
142. LEFERE S, Mosca A, Hudert C, Dupont E, et al
     Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD.
     Hepatology. 2025;81:1276-1287.
     PubMed     Abstract available
     
     
     
143. HLADY RA, Zhao X, El Khoury LY, Wagner RT, et al
     Epigenetic heterogeneity hotspots in human liver disease progression.
     Hepatology. 2025;81:1197-1210.
     PubMed     Abstract available
     
     
     
144. STALLER DW, Panigrahi SS, Jayasinghe YP, Dong Y, et al
     A novel phosphodiesterase inhibitor for the treatment of chronic liver injury and metabolic diseases.
     Hepatology. 2025;81:1288-1303.
     PubMed     Abstract available
     
     
     
145. ZANUSO V, Rimassa L, Braconi C
     The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy.
     Hepatology. 2025;81:1365-1386.
     PubMed     Abstract available
     
     
     
146. KUREBAYASHI Y, Sakamoto M
     Macrotrabecular hepatocellular carcinoma: Unique immunovascular characteristics.
     Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001339.
     PubMed    
     
     
     
147. MOL B, Werner E, Culver EL, van der Meer AJ, et al
     Epidemiological and economical burden of cholestatic liver disease.
     Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001341.
     PubMed     Abstract available
     
     
     March 2025
148. AHN JC, Ng WH, Yeo YH, Kim HS, et al
     Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation.
     Hepatology. 2025 Mar 28. doi: 10.1097/HEP.0000000000001328.
     PubMed     Abstract available
     
     
     
149. GUO Y, Wang J, Zhang L, Shen S, et al
     Erratum: Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma.
     Hepatology. 2025 Mar 27. doi: 10.1097/HEP.0000000000001240.
     PubMed    
     
     
     
150. KIM KE, Lee J, Shin HJ, Jeong EA, et al
     Erratum: Lipocalin-2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high-fat diet-fed Ob/Ob mice.
     Hepatology. 2025 Mar 27. doi: 10.1097/HEP.0000000000001287.
     PubMed    
     
     
     
151. MACIAS RIR, Roessler S, Verstegen MMA
     Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma.
     Hepatology. 2025 Mar 24. doi: 10.1097/HEP.0000000000001322.
     PubMed    
     
     
     
152. SU R, Tao X, Yan L, Liu Y, et al
     Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in chronic hepatitis B patients based on serum N-glycomics analysis: A cohort study.
     Hepatology. 2025 Mar 21. doi: 10.1097/HEP.0000000000001316.
     PubMed     Abstract available
     
     
     
153. TSENG TC, Hosaka T, Pan MH, Liu CJ, et al
     Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patients.
     Hepatology. 2025 Mar 20. doi: 10.1097/HEP.0000000000001313.
     PubMed     Abstract available
     
     
     
154. WONG CC, Wong CM
     CAD-Driven pathways in hepatocellular carcinoma metastasis.
     Hepatology. 2025 Mar 19. doi: 10.1097/HEP.0000000000001315.
     PubMed    
     
     
     
155. CHEN S, Shen L, Fan W
     Letter to the Editor: The divergences in the efficacy of adjuvant transarterial chemoembolization for hepatocellular carcinoma: In-depth analysis and enlightenments.
     Hepatology. 2025 Mar 18. doi: 10.1097/HEP.0000000000001310.
     PubMed    
     
     
     
156. ZHANG T, Huang CJ, Chen HT, Huang YH, et al
     HLA-DQB1*03:01 and risk of Hepatitis B virus-related hepatocellular carcinoma.
     Hepatology. 2025 Mar 14. doi: 10.1097/HEP.0000000000001307.
     PubMed     Abstract available
     
     
     
157. ZHAO Q, Liu H, Yang Z, Han X, et al
     Pre-B-Cell leukemia transcription factor 1 contributes to liver fibrosis by enabling IL-7 signaling in hepatic stellate cells.
     Hepatology. 2025 Mar 13. doi: 10.1097/HEP.0000000000001302.
     PubMed     Abstract available
     
     
     
158. PAN J, Zhang M, Rao D, Ma J, et al
     CAD manipulates tumor intrinsic DHO/UBE4B/NF-kappaB pathway and fuels macrophage cross-talk, promoting hepatocellular carcinoma metastasis.
     Hepatology. 2025 Mar 12. doi: 10.1097/HEP.0000000000001304.
     PubMed     Abstract available
     
     
     
159. MONTAGNESE S, Duarte-Rojo A
     Hepatic encephalopathy - We are no longer those who believe that reality is what we perceive.
     Hepatology. 2025 Mar 12. doi: 10.1097/HEP.0000000000001308.
     PubMed    
     
     
     
160. LI PJ, Tabrizian P, Daher D, Gaviria F, et al
     A prospective multicenter validation of RETREAT for post-transplantation hepatocellular carcinoma recurrence prediction.
     Hepatology. 2025 Mar 11. doi: 10.1097/HEP.0000000000001297.
     PubMed     Abstract available
     
     
     
161. AHN JC, Noh YK, Hu M, Shen X, et al
     AI-driven synthetic data generation for accelerating hepatology research: A study of the United Network for Organ Sharing (UNOS) database.
     Hepatology. 2025 Mar 11. doi: 10.1097/HEP.0000000000001299.
     PubMed     Abstract available
     
     
     
162. WANG P, Zhong L
     Letter to the Editor: Downstaging of hepatocellular carcinoma before liver transplantation: More details, more significance.
     Hepatology. 2025 Mar 10. doi: 10.1097/HEP.0000000000001301.
     PubMed    
     
     
     
163. XU E, Mehta N
     Reply: Downstaging of hepatocellular carcinoma before liver transplantation.
     Hepatology. 2025 Mar 10. doi: 10.1097/HEP.0000000000001303.
     PubMed    
     
     
     
164. CULLARO G, Allegretti AS, Patidar KR, Jamil K, et al
     The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: a post hoc analysis.
     Hepatology. 2025 Mar 7. doi: 10.1097/HEP.0000000000001295.
     PubMed     Abstract available
     
     
     
165. MOECKLI B, Wassmer CH, El Hajji S, Kumar R, et al
     Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study.
     Hepatology. 2025 Mar 5. doi: 10.1097/HEP.0000000000001289.
     PubMed     Abstract available
     
     
     
166. SUN Y, Li T, Ding L, Wang J, et al
     Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT.
     Hepatology. 2025;81:791-807.
     PubMed     Abstract available
     
     
     
167. NAKATSUKA T, Tateishi R, Sato M, Hashizume N, et al
     Deep learning and digital pathology powers prediction of HCC development in steatotic liver disease.
     Hepatology. 2025;81:976-989.
     PubMed     Abstract available
     
     
     
168. SASAKI K, Rooge S, Gunewardena S, Hintz JA, et al
     Kupffer cell diversity maintains liver function in alcohol-associated liver disease.
     Hepatology. 2025;81:870-887.
     PubMed     Abstract available
     
     
     
169. HAN S, Fan H, Zhong G, Ni L, et al
     Nuclear KRT19 is a transcriptional corepressor promoting histone deacetylation and liver tumorigenesis.
     Hepatology. 2025;81:808-822.
     PubMed     Abstract available
     
     
     
170. KIM D, Shah M, Kim JH, Kim J, et al
     Integrative transcriptomic and genomic analyses unveil the IFI16 variants and expression as MASLD progression markers.
     Hepatology. 2025;81:962-975.
     PubMed     Abstract available
     
     
     
171. LIU LZ, Zhang Z, Zheng BH, Shi Y, et al
     Erratum: CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma.
     Hepatology. 2025;81:E113-E114.
     PubMed    
     
     
     
172. DHANASEKARAN R, Suzuki H, Lemaitre L, Kubota N, et al
     Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making.
     Hepatology. 2025;81:1038-1057.
     PubMed     Abstract available
     
     
     February 2025
173. TANIAI T, Shimada S, Akiyama Y, Hatano M, et al
     Integrative transcriptome profiling elucidates molecular and immunovascular characteristics of macrotrabecular hepatocellular carcinoma.
     Hepatology. 2025 Feb 26. doi: 10.1097/HEP.0000000000001284.
     PubMed     Abstract available
     
     
     
174. VOLKERT I, Grube J, Woitok MM, Mohamed MR, et al
     Selective genetic inactivation of Caspase 8 in hepatocytes ameliorates progression of MASH following Jnk deficiency.
     Hepatology. 2025 Feb 26. doi: 10.1097/HEP.0000000000001286.
     PubMed     Abstract available
     
     
     
175. LIAO W, Zhang Y, Wang J, Cui G, et al
     beta-Catenin regulates distinct pathways from YAP and suppresses ONECUT1 to drive hepatoblastoma development in mice and humans.
     Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001280.
     PubMed     Abstract available
     
     
     
176. HONG L, Mei J, Sun X, Wu Y, et al
     Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma.
     Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001283.
     PubMed     Abstract available
     
     
     
177. CARDOSO FS
     Letter to the Editor: Mean arterial pressure as a complex treatment target in patients with cirrhosis and acute kidney injury.
     Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001288.
     PubMed    
     
     
     
178. TADDEI TH, Brown DB, Yarchoan M, Mendiratta-Lala M, et al
     Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
     Hepatology. 2025 Feb 24. doi: 10.1097/HEP.0000000000001269.
     PubMed    
     
     
     
179. WANG ZC, Gao Q, Shi JY, Guo WJ, et al
     Erratum: Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.
     Hepatology. 2025 Feb 18. doi: 10.1097/HEP.0000000000001176.
     PubMed    
     
     
     
180. WONG GL, Chan HL
     Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination.
     Hepatology. 2025 Feb 18. doi: 10.1097/HEP.0000000000001273.
     PubMed    
     
     
     
181. CANCADO GGL, Deeb M, Gulamhusein AF
     Liver transplantation for cholestatic liver diseases: Timing & disease recurrence.
     Hepatology. 2025 Feb 17. doi: 10.1097/HEP.0000000000001268.
     PubMed     Abstract available
     
     
     
182. LEE EW, Saab S, Eghbalieh N, Ding PX, et al
     Coil or Plug-Assisted Retrograde transvenous obliteration (CARTO/PARTO) for treating portal hypertensive variceal bleeding: A multi-center, real-world 10-year retrospective study.
     Hepatology. 2025 Feb 5. doi: 10.1097/HEP.0000000000001255.
     PubMed     Abstract available
     
     
     
183. SOUZA M, Al-Sharif L, Antunes VLJ, Huang DQ, et al
     Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.
     Hepatology. 2025 Feb 4. doi: 10.1097/HEP.0000000000001254.
     PubMed     Abstract available
     
     
     
184. BURTIS AEC, DeNicola DMC, Ferguson ME, Santos RG, et al
     Ag-driven CD8 + T cell clonal expansion is a prominent feature of MASH in humans and mice.
     Hepatology. 2025;81:591-608.
     PubMed     Abstract available
     
     
     
185. MOGA L, Paradis V, Ferreira-Silva J, Gudavalli K, et al
     Performance of spleen stiffness measurement to rule out high-risk varices in patients with porto-sinusoidal vascular disorder.
     Hepatology. 2025;81:546-559.
     PubMed     Abstract available
     
     
     
186. EL-SERAG HB, Jin Q, Tayob N, Salem E, et al
     HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States.
     Hepatology. 2025;81:465-475.
     PubMed     Abstract available
     
     
     
187. FEIO-AZEVEDO R, Boesch M, Radenkovic S, van Melkebeke L, et al
     Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure.
     Hepatology. 2025;81:509-522.
     PubMed     Abstract available
     
     
     
188. WONG YJ, Chen VL, Abdulhamid A, Tosetti G, et al
     Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients.
     Hepatology. 2025;81:523-531.
     PubMed     Abstract available
     
     
     
189. DUARTE-ROJO A, Taouli B, Leung DH, Levine D, et al
     Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
     Hepatology. 2025;81:725-748.
     PubMed     Abstract available
     
     
     
190. MARINO L, Kim A, Ni B, Celi FS, et al
     Thyroid hormone action and liver disease, a complex interplay.
     Hepatology. 2025;81:651-669.
     PubMed     Abstract available
     
     
     January 2025
191. ZHANG Z, Zhang Z, Zhang Y, Li Y, et al
     Phosphoproteomics delineates hepatocellular carcinoma subtypes and pinpoints therapeutic targets.
     Hepatology. 2025 Jan 31. doi: 10.1097/HEP.0000000000001250.
     PubMed     Abstract available
     
     
     
192. LIU Q, Li J, Chen H, Song J, et al
     Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
     Hepatology. 2025 Jan 31. doi: 10.1097/HEP.0000000000001215.
     PubMed    
     
     
     
193. YOUNOSSI ZM, de Avila L, Racila A, Nader F, et al
     Prevalence and predictors of cirrhosis and portal hypertension in the united states.
     Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001243.
     PubMed     Abstract available
     
     
     
194. CHENG K, Cai N, Yang X, Li D, et al
     Short-term starvation boosts anti-PD-L1 therapy by reshaping tumor-associated macrophages in hepatocellular carcinoma.
     Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001244.
     PubMed     Abstract available
     
     
     
195. DESPLATS V, Haudebourg L, Verger N, Assaraf J, et al
     Acute encephalopathy without hyperammonemia has a different presentation than overt hepatic encephalopathy and displays similarly severe prognosis.
     Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001252.
     PubMed     Abstract available
     
     
     
196. SEO DH, Sung PS
     Reply: Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma_reply.
     Hepatology. 2025 Jan 28. doi: 10.1097/HEP.0000000000001253.
     PubMed    
     
     
     
197. LU Z, Wong CM
     The impact of LRP4 mutations on hepatocellular carcinoma recurrence and immunotherapy response.
     Hepatology. 2025 Jan 16. doi: 10.1097/HEP.0000000000001235.
     PubMed    
     
     
     
198. YANG DL, Ye L, Zeng FJ, Liu J, et al
     Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermedi
     Hepatology. 2025 Jan 15. doi: 10.1097/HEP.0000000000001229.
     PubMed     Abstract available
     
     
     
199. XU E, Tabrizian P, Gutierrez J, Hoteit M, et al
     Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multi-center prospective cohort study.
     Hepatology. 2025 Jan 14. doi: 10.1097/HEP.0000000000001231.
     PubMed     Abstract available
     
     
     
200. MA T, Bai X, Zhang Q, Chen W, et al
     Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial.
     Hepatology. 2025 Jan 14. doi: 10.1097/HEP.0000000000001233.
     PubMed     Abstract available
     
     
     
201. LIU D, Chen L, Wang Z, Li Z, et al
     Ubiquitination of TFEB increased intestinal permeability to aggravate metabolic dysfunction-associated steatohepatitis.
     Hepatology. 2025 Jan 10. doi: 10.1097/HEP.0000000000001214.
     PubMed     Abstract available
     
     
     
202. OBRADOVIC F, Vitello DJ, Hasjim BJ, Obayemi J, et al
     Comparing the cost of cirrhosis to other common chronic diseases: A longitudinal study in a large national insurance database.
     Hepatology. 2025 Jan 6. doi: 10.1097/HEP.0000000000001206.
     PubMed     Abstract available
     
     
     
203. ROCCARINA D, Saltini D, Adotti V, Rosi M, et al
     End-procedural adherence to recommended hemodynamic targets does not improve the outcome of elective tips in cirrhotic patients.
     Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001224.
     PubMed     Abstract available
     
     
     
204. KABELITZ MA, Hartl L, Schaub G, Tiede A, et al
     Identification of optimal portal pressure decrease to control ascites while minimizing hepatic encephalopathy after TIPS: A multicenter study.
     Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001219.
     PubMed     Abstract available
     
     
     
205. RONCA V, Davies SP, Oo YH, Lleo A, et al
     The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects.
     Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001225.
     PubMed     Abstract available
     
     
     
206. KWAK M, Kim HS, Jiang ZG, Yeo YH, et al
     MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
     Hepatology. 2025;81:228-237.
     PubMed     Abstract available
     
     
     
207. HOBEIKA C, Ronot M, Guiu B, Ferraioli G, et al
     Ultrasound-based steatosis grading system using 2D-attenuation imaging: An individual patient data meta-analysis with external validation.
     Hepatology. 2025;81:212-227.
     PubMed     Abstract available
     
     
     
208. KE C, Xiao C, Li J, Wu X, et al
     FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1.
     Hepatology. 2025;81:181-197.
     PubMed     Abstract available
     
     
     
209. 
     Erratum: Expression and functional significance of Twist1 in hepatocellular carcinoma: Its role in vasculogenic mimicry.
     Hepatology. 2025;81:E26-E27.
     PubMed    
     
     
     
210. WILECHANSKY RM
     Putting mean arterial pressure on the map as an AKI biomarker in cirrhosis.
     Hepatology. 2025;81:3-4.
     PubMed    
     
     
     December 2024
211. CELSA C, Cabibbo G, Pinato DJ
     Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
     Hepatology. 2024 Dec 25. doi: 10.1097/HEP.0000000000001217.
     PubMed    
     
     
     
212. SUN R, Liu K, Pan S, Ye Y, et al
     LRP4 mutations promote tumour progression and resistance to anti-PD-1 therapy in recurrent hepatocellular carcinoma.
     Hepatology. 2024 Dec 24. doi: 10.1097/HEP.0000000000001212.
     PubMed     Abstract available
     
     
     
213. MA S, Chen J, Li J
     Letter to the editor: Intrahepatic immunoglobulin A complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.
     Hepatology. 2024 Dec 23. doi: 10.1097/HEP.0000000000001197.
     PubMed    
     
     
     
214. TAO J, Wu Z, Liang Y, Wang J, et al
     Lhx2 specifically expressed in hepatic stellate cells promotes liver regeneration and inhibits liver fibrosis.
     Hepatology. 2024 Dec 18. doi: 10.1097/HEP.0000000000001201.
     PubMed     Abstract available
     
     
     
215. VUTIEN P, Barnard Giustini A, Kim NJ, Moon AM, et al
     Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death.
     Hepatology. 2024 Dec 17. doi: 10.1097/HEP.0000000000001183.
     PubMed     Abstract available
     
     
     
216. YANG Y, Ni Q, Li H, Sun J, et al
     Genomic and the tumor microenvironment heterogeneity in multifocal hepatocellular carcinoma.
     Hepatology. 2024 Dec 12. doi: 10.1097/HEP.0000000000001191.
     PubMed     Abstract available
     
     
     
217. ZHOU KQ, Zhong YC, Song MF, Sun YF, et al
     Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution.
     Hepatology. 2024 Dec 10. doi: 10.1097/HEP.0000000000001182.
     PubMed     Abstract available
     
     
     
218. CONDE DE LA ROSA L, Fabrega L, Torres S, Nunez S, et al
     Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity.
     Hepatology. 2024 Dec 9. doi: 10.1097/HEP.0000000000001184.
     PubMed     Abstract available
     
     
     
219. GONZALEZ-RECIO I, Goikoetxea-Usandizaga N, Rejano-Gordillo CM, Conter C, et al
     Modulatory effects of CNNM4 on Protein-L-Isoaspartyl-O-Methyltransferase repair function during Alcohol-Induced hepatic damage.
     Hepatology. 2024 Dec 6. doi: 10.1097/HEP.0000000000001156.
     PubMed     Abstract available
     
     
     
220. BROOKHART MA, Mayne TJ, Coombs C, Breskin A, et al
     Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.
     Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001174.
     PubMed     Abstract available
     
     
     
221. HUI RW, Chiu KW, Lee IC, Wang C, et al
     Multimodal multiphasic pre-operative image-based deep-learning predicts hepatocellular carcinoma outcomes after curative surgery.
     Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001180.
     PubMed     Abstract available
     
     
     
222. SENGUPTA S, Gill V, Mellinger JL
     Alcohol-associated liver disease and public health policies.
     Hepatology. 2024;80:1323-1341.
     PubMed     Abstract available
     
     
     
223. HAQUE LY, Leggio L
     Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder.
     Hepatology. 2024;80:1408-1423.
     PubMed     Abstract available
     
     
     
224. MAREK GW, Malhi H
     MetALD: Does it require a different therapeutic option?
     Hepatology. 2024;80:1424-1440.
     PubMed     Abstract available
     
     
     
225. NARAYANAN P, Wu T, Shah VH, Curtis BL, et al
     Insights into ALD and AUD diagnosis and prognosis: Exploring AI and multimodal data streams.
     Hepatology. 2024;80:1480-1494.
     PubMed     Abstract available
     
     
     
226. RAYA TONETTI F, Eguileor A, Mrdjen M, Pathak V, et al
     Gut-liver axis: Recent concepts in pathophysiology in alcohol-associated liver disease.
     Hepatology. 2024;80:1342-1371.
     PubMed     Abstract available
     
     
     
227. ABERG F, Jiang ZG, Cortez-Pinto H, Mannisto V, et al
     Alcohol-associated liver disease-Global epidemiology.
     Hepatology. 2024;80:1307-1322.
     PubMed     Abstract available
     
     
     
228. FU Y, Maccioni L, Wang XW, Greten TF, et al
     Alcohol-associated liver cancer.
     Hepatology. 2024;80:1462-1479.
     PubMed     Abstract available
     
     
     
229. ISRAELSEN M, Rungratanawanich W, Thiele M, Liangpunsakul S, et al
     Non-invasive tests for alcohol-associated liver disease.
     Hepatology. 2024;80:1390-1407.
     PubMed     Abstract available
     
     
     November 2024
230. VERCHER E, Covo-Vergara A, Conde E, Hernandez-Rueda M, et al
     Human T cells engineered with an HLA-A2-restricted murine T-cell receptor targeting Glypican 3 effectively control human hepatocellular carcinoma in mice.
     Hepatology. 2024 Nov 26. doi: 10.1097/HEP.0000000000001175.
     PubMed     Abstract available
     
     
     
231. HAN J, Shan D
     Letter to the Editor: Refining the role of HAF in hepatocellular carcinoma.
     Hepatology. 2024 Nov 21. doi: 10.1097/HEP.0000000000001171.
     PubMed    
     
     
     
232. SCHEINER B, Kang B, Balcar L, Radu IP, et al
     Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.
     Hepatology. 2024 Nov 21. doi: 10.1097/HEP.0000000000001163.
     PubMed     Abstract available
     
     
     
233. SUMMERS SA, Koh MY
     Reply: Refining the role of HAF in hepatocellular carcinoma.
     Hepatology. 2024 Nov 21. doi: 10.1097/HEP.0000000000001173.
     PubMed    
     
     
     
234. WONG YJ, Teng M, Sim A, Abraldes JG, et al
     Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices.
     Hepatology. 2024 Nov 12. doi: 10.1097/HEP.0000000000001155.
     PubMed    
     
     
     
235. LEVY C, Bowlus CL
     Primary Biliary Cholangitis: personalizing second-line therapies.
     Hepatology. 2024 Nov 12. doi: 10.1097/HEP.0000000000001166.
     PubMed     Abstract available
     
     
     
236. JOHN BV, Bastaich D, Dahman B
     Reply: Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
     Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001162.
     PubMed    
     
     
     
237. KRIGE JE, Jonas EG, Bernon MM
     Letter to the editor: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices.
     Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001153.
     PubMed    
     
     
     
238. HE Z, Wang C, Tian H
     Letter to the editor : Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
     Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001159.
     PubMed    
     
     
     
239. BRUNO BJ, Weavil JC, Ogle J, Chidambaram N, et al
     Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial.
     Hepatology. 2024 Nov 8. doi: 10.1097/HEP.0000000000001146.
     PubMed     Abstract available
     
     
     
240. LI S, Wu Z
     Letter to the Editor: Enhancing automated speech analysis for hepatic encephalopathy detection.
     Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001150.
     PubMed    
     
     
     
241. LIAO TL, Chen DY, Hsieh SL, Yang YY, et al
     Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis via extracellular vesicles.
     Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001149.
     PubMed     Abstract available
     
     
     
242. ALVARADO-TAPIAS E, Brujats A, Puente A, Ardevol A, et al
     Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to beta-blockers: A double-blind, placebo-controlled, randomized-trial.
     Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001148.
     PubMed     Abstract available
     
     
     
243. BLOOM PP, Lok AS
     Reply: Enhancing automated speech analysis for hepatic encephalopathy detection.
     Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001151.
     PubMed    
     
     
     
244. CHARU V, Liang JW, Mannalithara A, Kwong A, et al
     Benchmarking clinical risk prediction algorithms with ensemble machine learning for the noninvasive diagnosis of liver fibrosis in NAFLD.
     Hepatology. 2024;80:1184-1195.
     PubMed     Abstract available
     
     
     
245. CHALASANI N, Vilar-Gomez E, Loomba R, Yates KP, et al
     PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.
     Hepatology. 2024;80:1212-1226.
     PubMed     Abstract available
     
     
     
246. STONEBRAKER JR, Pace RG, Gallins PJ, Dang H, et al
     Genetic variation in severe cystic fibrosis liver disease is associated with novel mechanisms for disease pathogenesis.
     Hepatology. 2024;80:1012-1025.
     PubMed     Abstract available
     
     
     
247. GE J, Sun S, Owens J, Galvez V, et al
     Development of a liver disease-specific large language model chat interface using retrieval-augmented generation.
     Hepatology. 2024;80:1158-1168.
     PubMed     Abstract available
     
     
     
248. ZHANG L, Jiao K, Liu Y, Xu G, et al
     UBXN9 inhibits the RNA exosome function to promote T cell control of liver tumorigenesis.
     Hepatology. 2024;80:1041-1057.
     PubMed     Abstract available
     
     
     
249. GAO W, Zhang L, Li Z, Wu T, et al
     Nuclear Acly protects the liver from ischemia-reperfusion injury.
     Hepatology. 2024;80:1087-1103.
     PubMed     Abstract available
     
     
     
250. 
     Erratum: NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
     Hepatology. 2024;80:E92.
     PubMed    
     
     
     
251. 
     Erratum: Basolateral CD147 induces hepatocyte polarity loss by E-cadherin ubiquitination and degradation in hepatocellular carcinoma progress.
     Hepatology. 2024;80:E91.
     PubMed    
     
     
     
252. 
     Erratum: Diagnosis, Evaluation, and Management of Ascites and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
     Hepatology. 2024;80:E89.
     PubMed    
     
     
     
253. NARAYANAN P
     PAR for the liver course: Preserving platelet function mitigates outcomes in cirrhosis.
     Hepatology. 2024;80:991-992.
     PubMed    
     
     
     October 2024
254. FAN G, Tao C, Li L, Xie T, et al
     The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma.
     Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001138.
     PubMed     Abstract available
     
     
     
255. VONADA A, Grompe M
     In vivo selection of hepatocytes.
     Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001143.
     PubMed     Abstract available
     
     
     
256. CIRIA R, Ivanics T, Aliseda D, Claasen M, et al
     Liver transplantation for primary and secondary liver tumours. patient-level meta-analyses compared to unos conventional indications.
     Hepatology. 2024 Oct 28. doi: 10.1097/HEP.0000000000001129.
     PubMed     Abstract available
     
     
     
257. KIM JW, Tung HC, Ke M, Xu P, et al
     The de-sulfinylation enzyme sulfiredoxin-1 attenuates hepatic stellate cell activation and liver fibrosis by modulating the PTPN12-NLRP3 axis.
     Hepatology. 2024 Oct 24. doi: 10.1097/HEP.0000000000001133.
     PubMed     Abstract available
     
     
     
258. ZHOU K, Wang Z, Guo W, Xie F, et al
     Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution.
     Hepatology. 2024 Oct 11. doi: 10.1097/HEP.0000000000001113.
     PubMed     Abstract available
     
     
     
259. KEZER CA, Berzigotti A, Fortune BE, Simonetto DA, et al
     Drug treatments to prevent first decompensation in cirrhosis.
     Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001117.
     PubMed     Abstract available
     
     
     
260. FAR A, Bastani A, Lee A, Gologorskaya O, et al
     Evaluating the positive predictive value of code-based identification of cirrhosis and its complications utilizing GPT-4.
     Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001115.
     PubMed     Abstract available
     
     
     
261. NAKAGAWA H
     New ubiquitomic subtypes in hepatocellular carcinoma: Insights for future therapeutic approaches.
     Hepatology. 2024 Oct 7. doi: 10.1097/HEP.0000000000001116.
     PubMed    
     
     
     
262. GIRI N, Niewisch MR, Rosenberg PS, Vittal A, et al
     Reply: Accurate predictor for liver disease progression in patients with DC/TBD.
     Hepatology. 2024;80:E61-E62.
     PubMed    
     
     
     
263. ZHAO J, Bi Y
     Letter to the Editor: Accurate predictor for liver disease progression in patients with DC/TBD.
     Hepatology. 2024;80:E60.
     PubMed    
     
     
     
264. EL-SHABRAWI MHF, Elamin A, Kamal NM
     Letter to the Editor: MAFLD versus MASLD criteria debate- Certainly not for children!
     Hepatology. 2024;80:E55-E56.
     PubMed    
     
     
     
265. LA VECCHIA C, Santucci C
     Liver cancer in young adults: Validity of global data sets.
     Hepatology. 2024;80:766-769.
     PubMed    
     
     
     
266. DANPANICHKUL P, Aboona MB, Sukphutanan B, Kongarin S, et al
     Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019.
     Hepatology. 2024;80:828-843.
     PubMed     Abstract available
     
     
     
267. CHEUNG KS, Ng HY, Hui RWH, Lam LK, et al
     Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
     Hepatology. 2024;80:916-927.
     PubMed     Abstract available
     
     
     
268. TANG S, Borlak J
     Genomics of human NAFLD: Lack of data reproducibility and high interpatient variability in drug target expression as major causes of drug failures.
     Hepatology. 2024;80:901-915.
     PubMed     Abstract available
     
     
     
269. SU GL, Zhang P, Belancourt PX, Youles B, et al
     Incorporation of quantitative imaging data using artificial intelligence improves risk prediction in veterans with liver disease.
     Hepatology. 2024;80:928-936.
     PubMed     Abstract available
     
     
     
270. PENRICE DD, Jalan-Sakrikar N, Jurk D, Passos JF, et al
     Telomere dysfunction in chronic liver disease: The link from aging.
     Hepatology. 2024;80:951-964.
     PubMed    
     
     
     
271. SAMPLE JW
     Beyond monotherapy: Combining radiotherapy with sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.
     Hepatology. 2024;80:757-758.
     PubMed    
     
     
     September 2024
272. LIN XT, Luo YD, Mao C, Gong Y, et al
     Integrated ubiquitomics characterization of hepatocellular carcinomas.
     Hepatology. 2024 Sep 30. doi: 10.1097/HEP.0000000000001096.
     PubMed     Abstract available
     
     
     
273. KODAMA T
     Geographical and molecular disparity of HBV integration: Implications for hepatocarcinogenesis and clinical outcomes in HCC.
     Hepatology. 2024 Sep 30. doi: 10.1097/HEP.0000000000001111.
     PubMed    
     
     
     
274. NOUREDDIN M, Truong E, Mayo R, Martinez-Arranz I, et al
     Letter to the Editor: Serum identification of At-Risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).
     Hepatology. 2024 Sep 26. doi: 10.1097/HEP.0000000000001061.
     PubMed    
     
     
     
275. AJOUAOU Y, Sadler KC
     Uncovering epigenetic heterogeneity in hepatocellular carcinoma.
     Hepatology. 2024 Sep 18. doi: 10.1097/HEP.0000000000001097.
     PubMed    
     
     
     
276. LYU X, Sze KM, Lee JM, Husain A, et al
     Disparity landscapes of viral-induced structural variations in hepatocellular carcinoma: Mechanistic characterization and functional implications.
     Hepatology. 2024 Sep 13. doi: 10.1097/HEP.0000000000001087.
     PubMed     Abstract available
     
     
     
277. BLOOM PP, Fisher CJ, Tedesco N, Kamdar N, et al
     HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy.
     Hepatology. 2024 Sep 12. doi: 10.1097/HEP.0000000000001086.
     PubMed     Abstract available
     
     
     
278. ACUNA-PILARTE K, Reichert EC, Song Green Y, Halberg LM, et al
     HAF prevents hepatocyte apoptosis and progression to MASH and hepatocellular carcinoma through transcriptional regulation of the NF-kappaB pathway.
     Hepatology. 2024 Sep 10. doi: 10.1097/HEP.0000000000001070.
     PubMed     Abstract available
     
     
     
279. JOHN BV, Bastaich D, Amoli MM, Wong RJ, et al
     Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
     Hepatology. 2024 Sep 10. doi: 10.1097/HEP.0000000000001092.
     PubMed     Abstract available
     
     
     
280. YOUNOSSI ZM, Stepanova M, Racila A, Henry L, et al
     Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis.
     Hepatology. 2024 Sep 6. doi: 10.1097/HEP.0000000000001084.
     PubMed     Abstract available
     
     
     
281. WU Y, Li L, Li W, Li N, et al
     Stretch-induced hepatic endothelial mechanocrine promotes hepatocyte proliferation.
     Hepatology. 2024 Sep 6. doi: 10.1097/HEP.0000000000001082.
     PubMed     Abstract available
     
     
     
282. 
     Hepatology Highlights.
     Hepatology. 2024;80:501-502.
     PubMed    
     
     
     
283. VILLANI R, Serviddio G
     Letter to the Editor: Multifactorial steatotic liver disease: A new entity to be included in new international classification of liver steatosis.
     Hepatology. 2024;80:E40-E41.
     PubMed    
     
     
     
284. ALBORAIE M, Fouad Y, Eslam M
     Letter to the Editor: MAFLD versus MASLD-Which is more appropriate from a global perspective?
     Hepatology. 2024;80:E42-E43.
     PubMed    
     
     
     
285. CHUNG SW, Moon HS, Shin H, Han H, et al
     Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study.
     Hepatology. 2024;80:633-648.
     PubMed     Abstract available
     
     
     
286. TERBAH R, Testro AG, Hoermann R, Majumdar A, et al
     Continuous home terlipressin infusion increases handgrip strength and reduces ascites-A prospective randomized crossover study.
     Hepatology. 2024;80:605-620.
     PubMed     Abstract available
     
     
     
287. WATLING CZ, Wojt A, Florio AA, Butera G, et al
     Fiber and whole grain intakes in relation to liver cancer risk: An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies.
     Hepatology. 2024;80:552-565.
     PubMed     Abstract available
     
     
     
288. LIN P, Yan X, Jing S, Wu Y, et al
     Single-cell and spatially resolved transcriptomics for liver biology.
     Hepatology. 2024;80:698-720.
     PubMed     Abstract available
     
     
     
289. 
     Hepatology Highlights.
     Hepatology. 2024;80:501-502.
     PubMed    
     
     
     August 2024
290. FACCIOLI LA, Sun Y, Animasahun O, Motomura T, et al
     Human induced pluripotent stem cell based hepatic-modeling of lipid metabolism associated TM6SF2 E167K variant.
     Hepatology. 2024 Aug 27. doi: 10.1097/HEP.0000000000001065.
     PubMed     Abstract available
     
     
     
291. LUCAS MR, Pilling LC, Atkins JL, Melzer D, et al
     Incidence of liver complications with hemochromatosis associated HFE p.C282Y homozygosity: The role of central adiposity.
     Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001056.
     PubMed     Abstract available
     
     
     
292. VAN DER MEER AJ, Sonneveld MJ
     Towards risk-based surveillance for hepatocellular carcinoma after HCV cure?
     Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001057.
     PubMed    
     
     
     
293. LIM HY, Heo J, Peguero JA, Ryoo BY, et al
     Efficacy and safety of bintrafusp alfa in two phase 1 expansion cohorts with advanced hepatocellular carcinoma.
     Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001054.
     PubMed     Abstract available
     
     
     
294. BJORNSSON ES, Devarbhavi HC
     Drug induced cholestatic liver diseases.
     Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001052.
     PubMed     Abstract available
     
     
     
295. SHANG Y, Akbari C, Dodd M, Zhang X, et al
     Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic metabolic dysfunction-associated steatotic liver disease.
     Hepatology. 2024 Aug 7. doi: 10.1097/HEP.0000000000001045.
     PubMed     Abstract available
     
     
     
296. NAULT JC, Iavarone M
     Management of patients with advanced hepatocellular carcinoma receiving atezolizumab/bevacizumab: Take care of cirrhosis!
     Hepatology. 2024 Aug 5. doi: 10.1097/HEP.0000000000001047.
     PubMed    
     
     
     
297. 
     Hepatology Highlights.
     Hepatology. 2024;80:255-256.
     PubMed    
     
     
     
298. GARCIA-TSAO G, Kaplan DE
     Reply: Endoscopy for potential variceal bleeding within 12 hours-Not so fast!
     Hepatology. 2024;80:E36.
     PubMed    
     
     
     
299. RAMAN KP, Patch D
     Tranexamic acid in variceal bleeding revisited.
     Hepatology. 2024;80:257-259.
     PubMed    
     
     
     
300. JEPSEN P, West J, Kann AE, Kraglund F, et al
     Risk of alcohol-associated liver disease in the offspring of parents with alcohol-associated liver disease: A nationwide cohort study.
     Hepatology. 2024;80:418-427.
     PubMed     Abstract available
     
     
     
301. WANG Q, Bu Q, Pan B, Yin Y, et al
     Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury.
     Hepatology. 2024;80:E24-E25.
     PubMed    
     
     
     
302. YANG D, Tian T, Li X, Zhang B, et al
     ZNT1 and Zn 2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor.
     Hepatology. 2024;80:312-329.
     PubMed     Abstract available
     
     
     
303. HLADY RA, Robertson KD
     Epigenetic memory of environmental exposures as a mediator of liver disease.
     Hepatology. 2024;80:451-464.
     PubMed     Abstract available
     
     
     July 2024
304. LIM N, Devuni D, German M, Guy J, et al
     The rise of multidisciplinary clinics in hepatology: A practical, how-to-guide, and review of the literature.
     Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001036.
     PubMed     Abstract available
     
     
     
305. WANG X, Liu Y, Zhang S, Zhang J, et al
     Genomic and transcriptomic analyses of chemical hepatocarcinogenesis aggravated by oncoprotein loss.
     Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001037.
     PubMed     Abstract available
     
     
     
306. WANG M, Chiou SH, Ganger D, Ruck J, et al
     Liver transplantation provides survival benefit at all levels of frailty: From the Multicenter Functional Assessment in Liver Transplantation Study.
     Hepatology. 2024 Jul 24. doi: 10.1097/HEP.0000000000001030.
     PubMed     Abstract available
     
     
     
307. JEONG JM, Choi SE, Shim YR, Kim HH, et al
     CX3CR1+ macrophages interact with hepatic stellate cells to promote hepatocellular carcinoma through CD8+ T cell suppression.
     Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001021.
     PubMed     Abstract available
     
     
     
308. CELSA C, Cabibbo G, Fulgenzi CAM, Battaglia S, et al
     Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
     Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001026.
     PubMed     Abstract available
     
     
     
309. 
     Diagnosis and Management of Hepatocellular Carcinoma.
     Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001010.
     PubMed    
     
     
     
310. ZHANG L, Xie P, Li M, Zhang X, et al
     Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.
     Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000001003.
     PubMed     Abstract available
     
     
     
311. HUANG Y, Yu F, Ding Y, Zhang H, et al
     Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver.
     Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000000998.
     PubMed     Abstract available
     
     
     
312. HOOVER JM
     Letter to the Editor: Utilization of beta blockers in patients with portal hypertension and peripheral artery disease.
     Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001008.
     PubMed    
     
     
     
313. KENT D, Ng SS, Syanda AM, Khoshkenar P, et al
     Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.
     Hepatology. 2024 Jul 2. doi: 10.1097/HEP.0000000000000969.
     PubMed     Abstract available
     
     
     
314. 
     Erratum: A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding.
     Hepatology. 2024;80:E23.
     PubMed    
     
     
     
315. 
     Hepatology Highlights.
     Hepatology. 2024;80:1-2.
     PubMed    
     
     
     
316. LAINE L, Barkun AN, Leontiadis GI
     Letter to the Editor: Endoscopy for potential variceal bleeding within 12 hours-Not so fast!
     Hepatology. 2024;80:E15-E16.
     PubMed    
     
     
     
317. KRAWCZYK M, Lammert F
     Letter to the Editor: NAFLD vs. MASLD-There ain't no such thing as a free lunch.
     Hepatology. 2024;80:E11-E12.
     PubMed    
     
     
     
318. RINELLA ME, Lazarus JV, Newsome PN
     Reply: NAFLD vs. MASLD-There ain't no such thing as a free lunch.
     Hepatology. 2024;80:E13-E14.
     PubMed    
     
     
     
319. MA J, Liangpunsakul S
     Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation.
     Hepatology. 2024;80:14-17.
     PubMed    
     
     
     
320. DAVENPORT M
     Serum matrix metalloproteinase-7 (MMP-7): As good as it gets?
     Hepatology. 2024;80:18-19.
     PubMed    
     
     
     
321. WOLTERS F, Oude Elferink RPJ, Beuers U
     PPARalpha, PPARdelta, or both-that is the question!
     Hepatology. 2024;80:8-10.
     PubMed    
     
     
     
322. KOSHIOL J, Krawczyk M
     enHanCCing knowledge of genetic factors in primary liver tumor.
     Hepatology. 2024;80:11-13.
     PubMed    
     
     
     
323. NEIL DAH, Smith ML, Minervini M, Demetris AJ, et al
     Reply: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
     Hepatology. 2024;80:E6-E7.
     PubMed    
     
     
     
324. CAO H, Gu J
     Letter to the Editor: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
     Hepatology. 2024;80:E4-E5.
     PubMed    
     
     
     
325. ABERG F, Asteljoki J, Mannisto V, Luukkonen PK, et al
     Combined use of the CLivD score and FIB-4 for prediction of liver-related outcomes in the population.
     Hepatology. 2024;80:163-172.
     PubMed     Abstract available
     
     
     
326. FLORIS A, Chandla S, Lim Y, Barbier-Torres L, et al
     Sumoylation of methionine adenosyltransferase alpha 1 promotes mitochondrial dysfunction in alcohol-associated liver disease.
     Hepatology. 2024;80:102-118.
     PubMed     Abstract available
     
     
     
327. LOPEZ-PASCUAL A
     Navigating liver disease complexity: Innovations in in vitro modeling and precision medicine.
     Hepatology. 2024;80:20-23.
     PubMed    
     
     
     
328. SCHONFELD M, O'Neil M, Weinman SA, Tikhanovich I, et al
     Alcohol-induced epigenetic changes prevent fibrosis resolution after alcohol cessation in miceresolution.
     Hepatology. 2024;80:119-135.
     PubMed     Abstract available
     
     
     
329. TONG Y, Wang F, Li S, Guo W, et al
     Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.
     Hepatology. 2024;80:38-54.
     PubMed     Abstract available
     
     
     
330. SINGAL AK, Shah VH, Malhi H
     Emerging targets for therapy in ALD: Lessons from NASH.
     Hepatology. 2024;80:223-237.
     PubMed     Abstract available
     
     
     
331. 
     Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
     Hepatology. 2024;80:E21.
     PubMed    
     
     
     
332. PREMKUMAR M, Karvellas CJ, Kulkarni AV, Bhujade H, et al
     Role of Point-of-Care ultrasound (POCUS) in clinical hepatology.
     Hepatology. 2024 Jul 1. doi: 10.1097/HEP.0000000000000990.
     PubMed     Abstract available
     
     
     June 2024
333. GAO D, Ping Yam JW
     Reversal of lipid metabolism as a therapeutic approach for hepatocellular carcinoma.
     Hepatology. 2024 Jun 27. doi: 10.1097/HEP.0000000000001000.
     PubMed    
     
     
     
334. PREMKUMAR M, Kulkarni A, Izzy M
     'Regarding Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography'.
     Hepatology. 2024 Jun 26. doi: 10.1097/HEP.0000000000000988.
     PubMed    
     
     
     
335. LUO X, Yu J
     Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury.
     Hepatology. 2024 Jun 25. doi: 10.1097/HEP.0000000000000984.
     PubMed    
     
     
     
336. RATZIU V, Yilmaz Y, Lazas D, Friedman SL, et al
     Aramchol improves hepatic fibrosis in MASH: Results of multimodality assessment using both conventional and digital pathology.
     Hepatology. 2024 Jun 25. doi: 10.1097/HEP.0000000000000980.
     PubMed     Abstract available
     
     
     
337. KANG K, Wu Y
     Letter to the Editor: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
     Hepatology. 2024 Jun 21. doi: 10.1097/HEP.0000000000000945.
     PubMed    
     
     
     
338. LI J, Ma X, Xuan Q, Li Q, et al
     Modulation of monocyte activity by hepatocellular MicroRNA delivery via hepatitis B virus surface antigen particles: Implications for pathobiology of chronic hepatitis B.
     Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000972.
     PubMed     Abstract available
     
     
     
339. YANG M, Song X, Zhang F, Li M, et al
     Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse.
     Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000979.
     PubMed     Abstract available
     
     
     
340. BERENGUER J, Bellon JM, Banares R, Gonzalez-Garcia J, et al
     Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
     Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000977.
     PubMed    
     
     
     
341. LIU Q, Zhang X, Qi J, Tian X, et al
     Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for hepatocellular carcinoma.
     Hepatology. 2024 Jun 19. doi: 10.1097/HEP.0000000000000962.
     PubMed     Abstract available
     
     
     
342. SIMONETTO DA, Winder GS, Connor AA, Terrault NA, et al
     Liver transplantation for Alcohol-associated liver disease.
     Hepatology. 2024 Jun 18. doi: 10.1097/HEP.0000000000000978.
     PubMed     Abstract available
     
     
     
343. 
     Process Measures to Improve Outcomes During Peri-Procedure Management of Coagulopathy in Cirrhosis.
     Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000964.
     PubMed    
     
     
     
344. HUANG L, Zou L
     Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
     Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
     PubMed    
     
     
     
345. 
     Erratum: Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.
     Hepatology. 2024;79:E171-E172.
     PubMed    
     
     
     
346. 
     Hepatology Highlights.
     Hepatology. 2024;79:1239-1240.
     PubMed    
     
     
     
347. LI Z, Zhang Y, Li Y, Lan J, et al
     Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC.
     Hepatology. 2024;79:E169-E170.
     PubMed    
     
     
     
348. LOMBARDI R, Dalbeni A, Mantovani A, Ravaioli F, et al
     Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
     Hepatology. 2024;79:E155-E156.
     PubMed    
     
     
     
349. CALZADILLA-BERTOT L, Jeffrey AW, Jeffrey GP
     Letter to the Editor: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
     Hepatology. 2024;79:E153-E154.
     PubMed    
     
     
     
350. YEH JG, Newsome PN
     Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
     Hepatology. 2024;79:1255-1257.
     PubMed    
     
     
     
351. HANSEN BE, Vandriel SM, Vig P, Garner W, et al
     Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
     Hepatology. 2024;79:1279-1292.
     PubMed     Abstract available
     
     
     
352. ABDELMALEK MF, Rinella ME
     Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart.
     Hepatology. 2024;79:1252-1254.
     PubMed    
     
     
     
353. ENGSTROM A, Wintzell V, Melbye M, Svanstrom H, et al
     Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
     Hepatology. 2024;79:1401-1411.
     PubMed     Abstract available
     
     
     
354. ZHAO G, Ma Q, Yang H, Jiang H, et al
     Base editing of the mutated TERT promoter inhibits liver tumor growth.
     Hepatology. 2024;79:1310-1323.
     PubMed     Abstract available
     
     
     
355. SCHMIDT KA, Simonetto DA
     The telomere tango: Liver disease in the genomic spotlight.
     Hepatology. 2024;79:1249-1251.
     PubMed    
     
     
     
356. SIDALI S, Borie R, Sicre de Fontbrune F, El Husseini K, et al
     Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors.
     Hepatology. 2024;79:1365-1380.
     PubMed     Abstract available
     
     
     
357. UMBAUGH DS, Nguyen NT, Curry SC, Rule JA, et al
     The chemokine CXCL14 is a novel early prognostic biomarker for poor outcome in acetaminophen-induced acute liver failure.
     Hepatology. 2024;79:1352-1364.
     PubMed     Abstract available
     
     
     
358. WANG A, Blackford AL, Behling C, Wilson LA, et al
     Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.
     Hepatology. 2024;79:1381-1392.
     PubMed     Abstract available
     
     
     
359. JIN Y, Shou Y, Lei Q, Du C, et al
     An entropy weight method to integrate big omics and mechanistically evaluate DILI.
     Hepatology. 2024;79:1264-1278.
     PubMed     Abstract available
     
     
     
360. AFONSO MB, Marques V, van Mil SWC, Rodrigues CMP, et al
     Human liver organoids: From generation to applications.
     Hepatology. 2024;79:1432-1451.
     PubMed     Abstract available
     
     
     May 2024
361. MANTOVANI S, Mondelli MU
     Platelets harness innate immunity to promote dissemination of hepatocellular carcinoma.
     Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000946.
     PubMed    
     
     
     
362. GUO C, Liu Z, Zhang T
     Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
     Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000947.
     PubMed    
     
     
     
363. MUSSO G, Pinach S, Mariano F, Saba F, et al
     Effect of phospholipid curcumin Meriva(R) on liver histology and kidney disease in nonalcoholic steatohepatitis a randomized, double-blind, placebo-controlled trial.
     Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000937.
     PubMed     Abstract available
     
     
     
364. LI B, Yang Y, Shi J, Li Y, et al
     Letter to the Editor: Molecular classification based on multi-omics facilitates prognostic stratification and personalized treatment in hepatocellular carcinoma.
     Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000944.
     PubMed    
     
     
     
365. MOORE MP, Wang X, Kennelly JP, Shi H, et al
     Low MBOAT7 expression, a genetic risk for MASH, promotes a pro-fibrotic pathway involving hepatocyte TAZ upregulation.
     Hepatology. 2024 May 22. doi: 10.1097/HEP.0000000000000933.
     PubMed     Abstract available
     
     
     
366. KANWAL F, Neuschwander-Tetri BA, Loomba R, Rinella ME, et al
     Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
     Hepatology. 2024;79:1212-1219.
     PubMed     Abstract available
     
     
     
367. NABI O, Lapidus N, Boursier J, de Ledinghen V, et al
     Reply: Concerns regarding the use of Fatty Liver Index in studies of lean NAFLD.
     Hepatology. 2024;79:E130-E131.
     PubMed    
     
     
     
368. ZAHRAWI FM, Mehal WZ
     Letter to the Editor: Concerns regarding the use of fatty liver index in studies of lean NAFLD.
     Hepatology. 2024;79:E129.
     PubMed    
     
     
     
369. STOCKDALE AJ, Degasperi E
     HDV RNA and liver disease progression: What do we know?
     Hepatology. 2024;79:983-985.
     PubMed    
     
     
     
370. DESERT R, Foucher F, Guillout M, Nieto N, et al
     Reply: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
     Hepatology. 2024;79:E141-E143.
     PubMed    
     
     
     
371. WANG TC, Xiao YD, Zhou P
     Letter to the Editor: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
     Hepatology. 2024;79:E140.
     PubMed    
     
     
     
372. LIU H, Li H, Wang DX, Li T, et al
     Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
     Hepatology. 2024;79:E144-E145.
     PubMed    
     
     
     
373. DALBENI A, Mantovani A, Lombardi R, Ravaioli F, et al
     Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
     Hepatology. 2024;79:E146-E147.
     PubMed    
     
     
     
374. KIRK FT, Munk DE, Swenson ES, Quicquaro AM, et al
     Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64 Cu PET/CT study in healthy humans.
     Hepatology. 2024;79:1065-1074.
     PubMed     Abstract available
     
     
     
375. SQUIRES JE, Horslen SP
     Incorporation of genetic testing into the diagnostic algorithms of PALF: The time is now.
     Hepatology. 2024;79:970-972.
     PubMed    
     
     
     
376. DALBENI A, Lombardi R, Henrique M, Zoncape M, et al
     Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
     Hepatology. 2024;79:1107-1116.
     PubMed     Abstract available
     
     
     
377. LENZ D, Schlieben LD, Shimura M, Bianzano A, et al
     Genetic landscape of pediatric acute liver failure of indeterminate origin.
     Hepatology. 2024;79:1075-1087.
     PubMed     Abstract available
     
     
     
378. AJMERA V, Tesfai K, Sandoval E, Lopez S, et al
     Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
     Hepatology. 2024;79:1098-1106.
     PubMed     Abstract available
     
     
     
379. TONIUTTO P, Shalaby S, Mameli L, Morisco F, et al
     Role of sex in liver tumor occurrence and clinical outcomes: A comprehensive review.
     Hepatology. 2024;79:1141-1157.
     PubMed     Abstract available
     
     
     
380. SANTOS AA, Delgado TC, Marques V, Ramirez-Moncayo C, et al
     Spatial metabolomics and its application in the liver.
     Hepatology. 2024;79:1158-1179.
     PubMed     Abstract available
     
     
     
381. 
     Erratum: Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma.
     Hepatology. 2024;79:E150-E151.
     PubMed    
     
     
     April 2024
382. KUMAR M, Venishetty S
     Reply: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - A randomized controlled trial.
     Hepatology. 2024 Apr 30. doi: 10.1097/HEP.0000000000000916.
     PubMed    
     
     
     
383. ELKRIEF L, Denecheau-Girard C, Magaz M, Praktiknjo M, et al
     Abdominal surgery in patients with chronic noncirrhotic extra hepatic portal vein obstruction: A multicenter retrospective study.
     Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000901.
     PubMed     Abstract available
     
     
     
384. LI X, Zhang Y, Li S, Shi J, et al
     Macrophage hitchhiking for systematic suppression in postablative multifocal hepatocellular carcinoma.
     Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000903.
     PubMed     Abstract available
     
     
     
385. CHOPRA SY, Rawat VL, Ingle MA, Lad SG, et al
     Letter to Editor: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
     Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000915.
     PubMed    
     
     
     
386. OCHOA-ALLEMANT P, Serper M, Wang RX, Tang H, et al
     Waitlisting and liver transplantation for MetALD in the United States: An analysis of the UNOS national registry.
     Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000914.
     PubMed     Abstract available
     
     
     
387. HITOMI Y, Ueno K, Aiba Y, Nishida N, et al
     A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis.
     Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000894.
     PubMed     Abstract available
     
     
     
388. LEE YT, Tseng HR, Yang JD
     Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block.
     Hepatology. 2024 Apr 19. doi: 10.1097/HEP.0000000000000898.
     PubMed    
     
     
     
389. GUO C, Liu Z, Fan H, Wang H, et al
     Machine learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis.
     Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000879.
     PubMed     Abstract available
     
     
     
390. HAZARI Y, Chevet E, Bailly-Maitre B, Hetz C, et al
     ER stress signaling at the interphase between MASH and hepatocellular carcinoma.
     Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000893.
     PubMed     Abstract available
     
     
     
391. PRZYBYSZEWSKI EM, Bhan I, Yarze JC
     Letter to the Editor: On the use of non-selective beta blockers in cirrhosis.
     Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000888.
     PubMed    
     
     
     
392. GARCIA-TSAO G, Kaplan DE
     Reply: On the use of non-selective beta blockers in cirrhosis.
     Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000889.
     PubMed    
     
     
     
393. VOLK ML
     Innovations in Healthcare Delivery for Patients with Cirrhosis.
     Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000892.
     PubMed    
     
     
     
394. MOGHE A, McGuire BM, Levy C
     Acute hepatic porphyrias - a guide for Hepatologists.
     Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000880.
     PubMed     Abstract available
     
     
     
395. SUN C, Zhou C, Daneshvar K, Ben Saad A, et al
     Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in hepatic stellate cells.
     Hepatology. 2024 Apr 2. doi: 10.1097/HEP.0000000000000822.
     PubMed     Abstract available
     
     
     
396. LI J, Allen AM, Yin M
     Reply: Comparing quantitative MRI technologies in steatotic liver disease.
     Hepatology. 2024;79:E121-E122.
     PubMed    
     
     
     
397. ALKHOURI N, Harisinghani M
     Letter to the Editor: Comparing quantitative MRI technologies in steatotic liver disease.
     Hepatology. 2024;79:E119-E120.
     PubMed    
     
     
     
398. FRANSES JW, Duda DG
     Scirrhous HCC: Another 'omic thread in the HCC tapestry.
     Hepatology. 2024;79:747-748.
     PubMed    
     
     
     
399. VOLKERT I, Fromme M, Schneider C, Candels L, et al
     Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
     Hepatology. 2024;79:898-911.
     PubMed     Abstract available
     
     
     
400. LADD AD, Duarte S, Sahin I, Zarrinpar A, et al
     Mechanisms of drug resistance in HCC.
     Hepatology. 2024;79:926-940.
     PubMed     Abstract available
     
     
     
401. 
     Erratum: Identification and characterization of a hepatic IL-13-producing ILC3-like population potentially involved in liver fibrosis.
     Hepatology. 2024;79:E128.
     PubMed    
     
     
     
402. 
     Erratum: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.
     Hepatology. 2024;79:E127.
     PubMed    
     
     
     
403. 
     April 2024 Hepatology Highlights.
     Hepatology. 2024;79:745-746.
     PubMed    
     
     
     
404. TAFALENG EN, Li J, Wang Y, Hidvegi T, et al
     Variants in autophagy genes MTMR12 and FAM134A are putative modifiers of the hepatic phenotype in alpha1-antitrypsin deficiency.
     Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000865.
     PubMed     Abstract available
     
     
     
405. TAPPER EB, Warner MA, Shah RP, Emamaullee J, et al
     Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi.
     Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000856.
     PubMed     Abstract available
     
     
     March 2024
406. 
     Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis.
     Hepatology. 2024 Mar 29. doi: 10.1097/HEP.0000000000000857.
     PubMed    
     
     
     
407. DENG T, Chen G
     Single-cell based molecular classification in systematic treatment of hepatocellular carcinoma: From in silico to bedside.
     Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000874.
     PubMed    
     
     
     
408. CRUZ C, Prado CM, Gillis C, Martindale R, et al
     Nutritional aspects of prehabilitation in adults with cirrhosis awaiting liver transplant.
     Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000818.
     PubMed     Abstract available
     
     
     
409. FENG X, Feng B, Zhou J, Yang J, et al
     Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells.
     Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000831.
     PubMed     Abstract available
     
     
     
410. GOLDBERG DT, Yaskolka Meir A, Tsaban G, Rinott E, et al
     Novel proteomic signatures may indicate MRI-assessed intrahepatic fat state and changes; the DIRECT PLUS clinical trial.
     Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000867.
     PubMed     Abstract available
     
     
     
411. ZHAO Q, Chen DP, Chen HD, Wang YZ, et al
     NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
     Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000868.
     PubMed     Abstract available
     
     
     
412. CHEN Y, Deng X, Li Y, Han Y, et al
     Comprehensive molecular classification predicted microenvironment profiles and therapy response for hepatocellular carcinoma.
     Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000869.
     PubMed     Abstract available
     
     
     
413. CULLARO G, Allegretti AS, Fenton C, Ge J, et al
     The association between mean arterial pressure and acute kidney injury reversal among decompensated cirrhosis patients.
     Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000858.
     PubMed     Abstract available
     
     
     
414. WIGG AJ, Narayana S, Woodman RJ, Adams LA, et al
     A randomized multicenter trial of a chronic disease management intervention for decompensated cirrhosis. The Australian Liver Failure (ALFIE) trial.
     Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000862.
     PubMed     Abstract available
     
     
     
415. MEROUEH C, Warasnhe K, Tizhoosh HR, Shah VH, et al
     Digital pathology and spatial omics in steatohepatitis: Clinical applications and discovery potentials.
     Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000866.
     PubMed     Abstract available
     
     
     
416. JONES DE, Beuers U, Bonder A, Carbone M, et al
     Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
     Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000864.
     PubMed     Abstract available
     
     
     
417. STERLING RK, Asrani SK, Levine D, Duarte-Rojo A, et al
     AASLD Practice Guideline on non-invasive liver disease assessments of portal hypertension.
     Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000844.
     PubMed    
     
     
     
418. STERLING RK, Patel K, Duarte-Rojo A, Asrani SK, et al
     AASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
     Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000845.
     PubMed    
     
     
     
419. STERLING RK, Duarte-Rojo A, Patel K, Asrani SK, et al
     AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
     Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000843.
     PubMed    
     
     
     
420. ROCKEY DC, Alsawas M, Rojo-Duarte A, Patel K, et al
     Non-invasive liver disease assessment to identify portal hypertension: A systematic review supporting the AASLD Practice Guideline.
     Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000841.
     PubMed     Abstract available
     
     
     
421. DIETZ-FRICKE C, Degasperi E, Jachs M, Maasoumy B, et al
     Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series.
     Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847.
     PubMed     Abstract available
     
     
     
422. MARCHETTI A, Pelusi S, Marella A, Malvestiti F, et al
     Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease.
     Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000839.
     PubMed     Abstract available
     
     
     
423. BU W, Sun X, Xue X, Geng S, et al
     Early onset of pathological polyploidization and cellular senescence in hepatocytes lacking RAD51 creates a pro-fibrotic and pro-tumorigenic inflammatory microenvironment.
     Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000821.
     PubMed     Abstract available
     
     
     
424. MUNOZ AE, Rodger EG
     Letter to the Editor: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
     Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000846.
     PubMed    
     
     
     
425. SHARPTON S, Loomba R
     Response to Letter to the Editor: emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
     Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000848.
     PubMed    
     
     
     
426. GUO Q, Wang J, Wang G, Wang X, et al
     Letter to the Editor: Is right heart assessment vital for evaluating Terlipressin-related outcomes in Hepatorenal Syndrome-AKI?
     Hepatology. 2024 Mar 8. doi: 10.1097/HEP.0000000000000832.
     PubMed    
     
     
     
427. CHAPMAN B, Wong D, Sinclair M, Hey P, et al
     Reversing malnutrition and low muscle strength with targeted enteral feeding in patients awaiting liver transplant: A randomized controlled trial.
     Hepatology. 2024 Mar 8. doi: 10.1097/HEP.0000000000000840.
     PubMed     Abstract available
     
     
     
428. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
     Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
     Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
     PubMed     Abstract available
     
     
     
429. SEMMLER G, Hartl L, Mendoza YP, Simbrunner B, et al
     Simple blood tests to diagnose compensated advanced chronic liver disease and stratify risk of clinically significant portal hypertension.
     Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000829.
     PubMed     Abstract available
     
     
     
430. AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
     Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
     Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
     PubMed     Abstract available
     
     
     
431. LAL BB, Alam S, Sibal A, Kumar K, et al
     Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis.
     Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000828.
     PubMed     Abstract available
     
     
     
432. ROY A, Kajal K, Izzy M, Sihag BK, et al
     Reply: Is right heart assessment vital for evaluating terlipressin-related outcomes in Hepatorenal Syndrome-AKI ?
     Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000833.
     PubMed    
     
     
     
433. KUMAR M, Venishetty S, Jindal A, Bihari C, et al
     Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
     Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000817.
     PubMed     Abstract available
     
     
     
434. 
     Erratum: An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
     Hepatology. 2024;79:E105.
     PubMed    
     
     
     
435. HOOFNAGLE JH, Doo E
     Letter to the Editor: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
     Hepatology. 2024;79:E91-E92.
     PubMed    
     
     
     
436. LAZARUS JV, Newsome PN, Francque SM, Kanwal F, et al
     Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
     Hepatology. 2024;79:E93-E94.
     PubMed    
     
     
     
437. BARMAN-AKSOZEN J, Minder AE, Schuppan D, Stolzel U, et al
     Letter to the Editor: Contrasting effect of iron supplementation in protoporphyria.
     Hepatology. 2024;79:E87-E88.
     PubMed    
     
     
     
438. LEVY C, Dickey AK, Anderson KE, Keel SB, et al
     Reply: Contrasting effect of iron supplementation in protoporphyria.
     Hepatology. 2024;79:E89-E90.
     PubMed    
     
     
     
439. NICOARA-FARCAU O, Han G, Rudler M, Angrisani D, et al
     Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis.
     Hepatology. 2024;79:624-635.
     PubMed     Abstract available
     
     
     
440. WANG F, Chen L, Kong D, Zhang X, et al
     Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1alpha transcriptional complex.
     Hepatology. 2024;79:606-623.
     PubMed     Abstract available
     
     
     
441. LEE BP, Dodge JL, Terrault NA
     National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
     Hepatology. 2024;79:666-673.
     PubMed     Abstract available
     
     
     
442. BARTEN TRM, Atsma F, van der Meer AJ, Gansevoort R, et al
     Higher need for polycystic liver disease therapy in female patients: Sex-specific association between liver volume and need for therapy.
     Hepatology. 2024;79:551-559.
     PubMed     Abstract available
     
     
     
443. LEDENKO M, Antwi SO, Patel T
     Geospatial analysis of cyanobacterial exposure and liver cancer in the contiguous United States.
     Hepatology. 2024;79:575-588.
     PubMed     Abstract available
     
     
     
444. LEVY C, Dickey AK, Wang B, Thapar M, et al
     Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria.
     Hepatology. 2024;79:731-743.
     PubMed    
     
     
     
445. 
     Hepatology Highlights.
     Hepatology. 2024;79:525-526.
     PubMed    
     
     
     February 2024
446. WONG YJ, Teng M, Sim A, Thet HM, et al
     Full adherence to cirrhosis quality indicators is associated with lower mortality in acute variceal bleeding: Nationwide audit.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000793.
     PubMed     Abstract available
     
     
     
447. HASSAN MM, Li D, Han Y, Byun J, et al
     Genome-wide association study identifies high-impact susceptibility loci for hepatocellular carcinoma in North America.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000800.
     PubMed     Abstract available
     
     
     
448. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
     Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
     PubMed     Abstract available
     
     
     
449. PENG Z, Wei G, Huang P, Matta H, et al
     ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000801.
     PubMed     Abstract available
     
     
     
450. HE B, Huang Z, Qin S, Peng P, et al
     Enhanced SLC35B2/SAV1 sulfation axis promotes tumor growth through inhibiting Hippo signaling in hepatocellular carcinoma.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000783.
     PubMed     Abstract available
     
     
     
451. CALTHORPE L, Chiou SH, Rubin J, Huang CY, et al
     A modified hospital frailty risk score for patients with cirrhosis undergoing abdominal operations.
     Hepatology. 2024 Feb 19. doi: 10.1097/HEP.0000000000000794.
     PubMed     Abstract available
     
     
     
452. PREMKUMAR M, Kajal K, Izzy M, Sihag BK, et al
     Reply to 'liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus".
     Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000792.
     PubMed    
     
     
     
453. PAPATHERODORIDIS G, Lampertico P
     Hepatocellular carcinoma risk in HBeAg-positive chronic hepatitis B patients under long-term nucleos(t)ide analogue therapy: New insights from Asia.
     Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000796.
     PubMed    
     
     
     
454. ZHU M, Liu Z, Chen S, Luo Z, et al
     Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study.
     Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000776.
     PubMed     Abstract available
     
     
     
455. PARK JG, Roh PR, Kang MW, Cho SW, et al
     Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.
     Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000772.
     PubMed     Abstract available
     
     
     
456. DONGELMANS E, Erler N, Adam R, Nadalin S, et al
     Recent outcomes of liver transplantation for Budd Chiari Syndrome - a study of the European Liver Transplant Registry (ELTR) and affiliated centers.
     Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000778.
     PubMed     Abstract available
     
     
     
457. AGRAWAL D, Ariga KK
     Liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus.
     Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000789.
     PubMed    
     
     
     
458. ALLEGRETTI AS, Patidar KR, Ma AT, Cullaro G, et al
     From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.
     Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000790.
     PubMed     Abstract available
     
     
     
459. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
     Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
     Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
     PubMed    
     
     
     
460. EHRENBAUER AF, Egge JFM, Gabriel MM, Tiede A, et al
     Comparison of six tests for diagnosing minimal hepatic encephalopathy and predicting clinical outcome - A prospective, observational study.
     Hepatology. 2024 Feb 13. doi: 10.1097/HEP.0000000000000770.
     PubMed     Abstract available
     
     
     
461. RINELLA ME, Castro Narro GE, Krag A, Terrault N, et al
     Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' dagger.
     Hepatology. 2024;79:E16-E17.
     PubMed    
     
     
     
462. CUSI K, Younossi Z, Roden M
     From NAFLD to MASLD: Promise and pitfalls of a new definition dagger.
     Hepatology. 2024;79:E13-E15.
     PubMed    
     
     
     
463. BALAKRISHNAN M, Rehm J
     A public health perspective on mitigating the global burden of chronic liver disease.
     Hepatology. 2024;79:451-459.
     PubMed     Abstract available
     
     
     
464. KHALID M, Khan ZM, Sheraz Kahloon A
     Letter to the Editor: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
     Hepatology. 2024;79:E18-E19.
     PubMed    
     
     
     
465. KIM Y, Chang Y, Ryu S, Wild SH, et al
     Reply: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
     Hepatology. 2024;79:E20-E21.
     PubMed    
     
     
     
466. BARR RG, Bolondi L
     Contrast-enhanced US for HCC: Finally out from the waiting list?
     Hepatology. 2024;79:267-268.
     PubMed    
     
     
     
467. LYSHCHIK A, Wessner CE, Bradigan K, Eisenbrey JR, et al
     Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe.
     Hepatology. 2024;79:380-391.
     PubMed     Abstract available
     
     
     
468. HUANG H, Tsui YM, Ho DW, Chung CY, et al
     LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress.
     Hepatology. 2024;79:323-340.
     PubMed     Abstract available
     
     
     
469. LAZARUS JV, Mark HE, Allen AM, Arab JP, et al
     A global action agenda for turning the tide on fatty liver disease.
     Hepatology. 2024;79:502-523.
     PubMed     Abstract available
     
     
     
470. MENG Z, Zhou L, Hong S, Qiu X, et al
     Myeloid-specific ablation of Basp1 ameliorates diet-induced NASH in mice by attenuating pro-inflammatory signaling.
     Hepatology. 2024;79:409-424.
     PubMed     Abstract available
     
     
     
471. SINHA S, Hassan N, Schwartz RE
     Organelle stress and alterations in interorganelle crosstalk during liver fibrosis.
     Hepatology. 2024;79:482-501.
     PubMed     Abstract available
     
     
     
472. 
     Hepatology Highlights.
     Hepatology. 2024;79:255-256.
     PubMed    
     
     
     
473. 
     Hepatology Highlights.
     Hepatology. 2024;79:255-256.
     PubMed    
     
     
     January 2024
474. 
     Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.
     Hepatology. 2024 Jan 29. doi: 10.1097/HEP.0000000000000730.
     PubMed    
     
     
     
475. WANG Y, Wang X, Bai B, Shaha A, et al
     Targeting Src SH3 domain-mediated glycolysis of hepatic stellate cells suppresses transcriptome, myofibroblastic activation, and colorectal liver metastasis.
     Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000763.
     PubMed     Abstract available
     
     
     
476. XIA Y, Wang Y, Xiong Q, He J, et al
     Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of hepatic stellate cells.
     Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000762.
     PubMed     Abstract available
     
     
     
477. 
     Hepatology highlights.
     Hepatology. 2024 Jan 23. doi: 10.1097/HEP.0000000000000742.
     PubMed    
     
     
     
478. NAKAGAWA H, Lin A
     The translation of oncogenic mRNAs regulated by pseudouridylation: A new player in hepatocellular carcinoma.
     Hepatology. 2024 Jan 22. doi: 10.1097/HEP.0000000000000761.
     PubMed    
     
     
     
479. NIEMIETZ P, Peiseler M, Kohlhepp M, Horn P, et al
     C-C chemokine receptor type 7 (CCR7) regulates hepatic CD8+ T cell homeostasis and response to acute liver injury.
     Hepatology. 2024 Jan 17. doi: 10.1097/HEP.0000000000000757.
     PubMed     Abstract available
     
     
     
480. TRIPODI A, Primignani M, D'Ambrosio R, Tosetti G, et al
     Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis.
     Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000756.
     PubMed     Abstract available
     
     
     
481. 
     Hepatology Highlights.
     Hepatology. 2024;79:1-2.
     PubMed    
     
     
     
482. BARGELLINI I, Rimassa L, Masi G
     SIRT and chemotherapy in unresectable iCCA: Ready to take off.
     Hepatology. 2024;79:9-11.
     PubMed    
     
     
     
483. EMANUELE E, Minoretti P
     Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with "Ludwig disease".
     Hepatology. 2024;79:E4.
     PubMed    
     
     
     
484. NEWSOME P, Rinella ME, Lazarus JV, Terrault N, et al
     Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease".
     Hepatology. 2024;79:E5-E6.
     PubMed    
     
     
     
485. ROWE IA
     Prediction of outcomes in patients with acute variceal bleeding.
     Hepatology. 2024;79:15-17.
     PubMed    
     
     
     
486. WANG CC, Cheng YM, Kao JH
     Letter to the Editor: Statement of steatotic liver disease-A great leap toward the global standardization.
     Hepatology. 2024;79:E7-E8.
     PubMed    
     
     
     
487. GARCIA-CRIADO A, Bruix J
     Screening for liver cancer: The good, the bad, and the ugly.
     Hepatology. 2024;79:12-14.
     PubMed    
     
     
     
488. CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
     Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
     Hepatology. 2024;79:39-48.
     PubMed     Abstract available
     
     
     
489. LEE EW, Eghtesad B, Garcia-Tsao G, Haskal ZJ, et al
     AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage.
     Hepatology. 2024;79:224-250.
     PubMed    
     
     
     
490. 
     Hepatology Highlights.
     Hepatology. 2024;79:1-2.
     PubMed    
     
     
     December 2023
491. HOFER BS, Brusilovskaya K, Simbrunner B, Balcar L, et al
     Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000740.
     PubMed     Abstract available
     
     
     
492. VAJRO P, Mandato C
     Letter to the Editor: More on Non-Alcohol/Non-Metabolic Dysfunction-Associated Steatohepatitis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000734.
     PubMed    
     
     
     
493. JENG WJ, Chien RN, Liaw YF
     Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737.
     PubMed    
     
     
     
494. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
     Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
     PubMed    
     
     
     
495. WIEGAND J, Franke A, Stein K, Trautwein C, et al
     Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
     PubMed    
     
     
     
496. WATT KD, Khan MQ
     Reply to "more on non-alcohol/non-metabolic dysfunction-associated steatohepatitis".
     Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000739.
     PubMed    
     
     
     
497. CHEN J, Tu T, Cohen C, Wang S, et al
     Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
     Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732.
     PubMed    
     
     
     
498. ZABRANSKY DJ, Yarchoan M, Ho WJ
     Reply: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
     Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000738.
     PubMed    
     
     
     
499. LU T, Zhang J, Li H, Li G, et al
     Letter to the Editor: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
     Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000733.
     PubMed    
     
     
     
500. KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
     Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
     Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
     PubMed     Abstract available
     
     
     
501. RATZIU V, Francque S, Behling CA, Cejvanovic V, et al
     Artificial intelligence scoring of liver biopsies in a phase ii trial of semaglutide in non-alcoholic steatohepatitis.
     Hepatology. 2023 Dec 19. doi: 10.1097/HEP.0000000000000723.
     PubMed     Abstract available
     
     
     
502. VOGEL A, Grant RC, Meyer T, Sapisochin G, et al
     Adjuvant and neoadjuvant therapies for hepatocellular carcinoma.
     Hepatology. 2023 Dec 18. doi: 10.1097/HEP.0000000000000726.
     PubMed     Abstract available
     
     
     
503. SIDDIQUI MS, Muthiah M, Satapathy SK, Patidar K, et al
     Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation.
     Hepatology. 2023 Dec 13. doi: 10.1097/HEP.0000000000000720.
     PubMed     Abstract available
     
     
     
504. SCHULZE RJ, Strom SC, Nyberg SL
     From pain to gain: Leveraging acetaminophen in hepatocyte transplantation for phenylketonuria.
     Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000713.
     PubMed    
     
     
     
505. YU S, Liu X, Xu Y, Pan L, et al
     m6A-mediated gluconeogenic enzyme PCK1 upregulation protects against hepatic ischemia-reperfusion injury.
     Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000716.
     PubMed     Abstract available
     
     
     
506. YIN C, Zhang C, Wang Y, Liu G, et al
     ALDOB/KAT2A interactions epigenetically modulate TGF-beta expression and T cell functions in hepatocellular carcinogenesis.
     Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000704.
     PubMed     Abstract available
     
     
     
507. CHAN FF, Yuen VW, Shen J, Chin DW, et al
     Inhibition of CAF-1 histone chaperone complex triggers cytosolic DNA and dsRNA sensing pathways and induces intrinsic immunity of hepatocellular carcinoma.
     Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000709.
     PubMed     Abstract available
     
     
     
508. MALHI H, Brown RS Jr, Lim JK, Reau N, et al
     Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals.
     Hepatology. 2023;78:1680-1681.
     PubMed    
     
     
     
509. RINELLA ME, Lazarus JV, Ratziu V, Francque SM, et al
     A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
     Hepatology. 2023;78:1966-1986.
     PubMed     Abstract available
     
     
     
510. DESAI AP, Madathanapalli A, Tang Q, Orman ES, et al
     PROMIS Profile-29 is a valid instrument with distinct advantages over legacy instruments for measuring the quality of life in chronic liver disease.
     Hepatology. 2023;78:1788-1799.
     PubMed     Abstract available
     
     
     
511. ABERG F
     Letter to the Editor: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
     Hepatology. 2023;78:E101-E102.
     PubMed    
     
     
     
512. RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
     Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
     Hepatology. 2023;78:E103-E104.
     PubMed    
     
     
     
513. ZHANG X, Yip TC, Tse YK, Hui VW, et al
     Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis.
     Hepatology. 2023;78:1816-1827.
     PubMed     Abstract available
     
     
     
514. GAO R, Li Y, Xu Z, Zhang F, et al
     Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease.
     Hepatology. 2023;78:1800-1815.
     PubMed     Abstract available
     
     
     
515. 
     Erratum: Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis.
     Hepatology. 2023;78:E110.
     PubMed    
     
     
     
516. 
     Erratum: Diabetes and cirrhosis: Current concepts on diagnosis and management.
     Hepatology. 2023;78:E108.
     PubMed    
     
     
     
517. 
     Erratum: Inhibition of mPGES-2 ameliorates non-alcoholic steatohepatitis by activating NR1D1 via heme.
     Hepatology. 2023;78:E107.
     PubMed    
     
     
     
518. MAIWALL R, Piano S, Singh V, Caraceni P, et al
     Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections- Results from the ICA 'Global study' [EABCIR-Global Study].
     Hepatology. 2023 Dec 1. doi: 10.1097/HEP.0000000000000653.
     PubMed     Abstract available
     
     
     
519. 
     Ending stigmatizing language in alcohol and liver disease: A liver societies' statement dagger.
     Hepatology. 2023;78:1682-1683.
     PubMed    
     
     
     November 2023
520. HU YX, Diao LT, Hou YR, Lv G, et al
     PUS1 promotes hepatocellular carcinoma via mRNA pseudouridylation to enhance the translation of oncogenic mRNAs.
     Hepatology. 2023 Nov 28. doi: 10.1097/HEP.0000000000000702.
     PubMed     Abstract available
     
     
     
521. PREMKUMAR M, Kajal K, Reddy KR, Izzy M, et al
     Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
     Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000691.
     PubMed     Abstract available
     
     
     
522. MICHALOPOULOS GK
     Hepatocytes of mice and men: Different regenerative signals?
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000693.
     PubMed    
     
     
     
523. KE L, Rui Z, Fukai W, Yunzheng Z, et al
     Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in hepatocellular carcinoma.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000673.
     PubMed     Abstract available
     
     
     
524. 
     February 2024 Hepatology Highlights.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000681.
     PubMed    
     
     
     
525. VAN DER MEEREN PE, Frederik de Wilde R, Sprengers D, IJzermans JNM, et al
     Benefit and harm of waiting time in liver transplantation for HCC.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000668.
     PubMed     Abstract available
     
     
     
526. LIU N, Tian J, Steer CJ, Han Q, et al
     MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux.
     Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000672.
     PubMed     Abstract available
     
     
     
527. KARVELLAS CJ, Bajaj JS, Kamath PS, Napolitano L, et al
     AASLD Practice guidance on Acute-on-chronic liver failure and the management of critically Ill patients with cirrhosis.
     Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000671.
     PubMed    
     
     
     
528. QASIM KHAN M, Hassan S, Lizaola-Mayo BC, Bhat M, et al
     Navigating the 'Specific Etiology' steatohepatitis category: Evaluation & management of non-alcohol/non-metabolic dysfunction-associated steatohepatitis.
     Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000674.
     PubMed    
     
     
     
529. BRENNER DA
     Alternatives to animal testing to assess NASH drugs and hepatotoxicity.
     Hepatology. 2023 Nov 6. doi: 10.1097/HEP.0000000000000669.
     PubMed     Abstract available
     
     
     
530. SCHERR AL, Nader L, Xu K, Elssner C, et al
     Etiology-independent activation of the LTbeta-LTbetaR-RELB axis drives aggressiveness and predicts poor prognosis in Hepatocellular carcinoma.
     Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000657.
     PubMed     Abstract available
     
     
     
531. D'AMICO G, Zipprich A, Villanueva C, Sorda JA, et al
     Further decompensation in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements.
     Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000652.
     PubMed     Abstract available
     
     
     
532. RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
     Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening.
     Hepatology. 2023;78:E91-E92.
     PubMed    
     
     
     
533. ARIAS-LOSTE MT, Crespo J, Iruzubieta P
     Letter to the Editor: Updated guidance on NAFLD screening.
     Hepatology. 2023;78:E89-E90.
     PubMed    
     
     
     
534. SEBASTIANI G, Milic J, Tsochatzis EA, Marzolini C, et al
     Letter to the Editor: People living with HIV and NAFLD-A population left behind in the global effort for liver fibrosis screening?
     Hepatology. 2023;78:E87-E88.
     PubMed    
     
     
     
535. YANG Z, Ding WX
     The pre-mRNA alternative splicing regulated by SRPK2: A new player in alcohol-associated liver disease?
     Hepatology. 2023;78:1329-1331.
     PubMed    
     
     
     
536. LAZARUS JV, Kopka CJ, Younossi ZM, Allen AM, et al
     It is time to expand the fatty liver disease community of practice.
     Hepatology. 2023;78:1325-1328.
     PubMed    
     
     
     
537. TILG H, Adolph TE, Tacke F
     Therapeutic modulation of the liver immune microenvironment.
     Hepatology. 2023;78:1581-1601.
     PubMed     Abstract available
     
     
     
538. NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
     ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
     Hepatology. 2023;78:1337-1351.
     PubMed     Abstract available
     
     
     
539. WU Q, Pan C, Zhou Y, Wang S, et al
     Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment.
     Hepatology. 2023;78:1402-1417.
     PubMed     Abstract available
     
     
     
540. SONG Y, Wei J, Li R, Fu R, et al
     Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-beta/SMAD signaling.
     Hepatology. 2023;78:1433-1447.
     PubMed     Abstract available
     
     
     
541. CHIU YT, Husain A, Sze KM, Ho DW, et al
     Midline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC.
     Hepatology. 2023;78:1368-1383.
     PubMed     Abstract available
     
     
     
542. YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
     Metabolic reprogramming and its clinical implication for liver cancer.
     Hepatology. 2023;78:1602-1624.
     PubMed     Abstract available
     
     
     
543. LEE CM, Yoon EL, Kim M, Kang BK, et al
     Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
     Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000664.
     PubMed     Abstract available
     
     
     
544. BRAILLON A, Naudet F
     Letter to the Editor: Medications promoting abstinence in alcohol-associated cirrhosis.
     Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000656.
     PubMed    
     
     
     October 2023
545. JENG WJ, Chien RN, Liaw YF
     Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
     PubMed    
     
     
     
546. DENG R, Wang Z, Liu Y, Sun J, et al
     Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
     PubMed    
     
     
     
547. GRATACOS-GINES J, Lopez-Pelayo H, Pose E
     Reply: Medications promoting abstinence in alcohol-associated cirrhosis.
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000660.
     PubMed    
     
     
     
548. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
     Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
     Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
     PubMed     Abstract available
     
     
     
549. SONG Y, Ye T, Roberts LR, Larson NB, et al
     Randomization in hepatology: A review of principles, opportunities, and challenges.
     Hepatology. 2023 Oct 24. doi: 10.1097/HEP.0000000000000649.
     PubMed     Abstract available
     
     
     
550. KAPLAN DE, Bosch J, Ripoll C, Thiele M, et al
     AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000647.
     PubMed    
     
     
     
551. YANG T, Qu X, Wang X, Xu D, et al
     Macrophage STING-YAP axis controls hepatic steatosis by promoting autophagic degradation of lipid droplets.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000638.
     PubMed     Abstract available
     
     
     
552. CHANG CW, Chen YS, Huang CH, Lin CH, et al
     A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000637.
     PubMed     Abstract available
     
     
     
553. OLIVA-VILARNAU N, Beusch CM, Sabatier P, Sakaraki E, et al
     Wnt/beta-catenin and NFkappaB signaling synergize to trigger growth-factor-free regeneration of adult primary human hepatocytes.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000648.
     PubMed     Abstract available
     
     
     
554. CAMPANI C, Vallot A, Ghannouchi H, Allaire M, et al
     Impact of radiological response and pattern of progression in patients with hepatocellular carcinoma treated by atezolizumab- bevacizumab.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000636.
     PubMed     Abstract available
     
     
     
555. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
     Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
     PubMed     Abstract available
     
     
     
556. DONGELMANS EJ, Sonneveld MJ, Janssen HLA
     Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
     Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639.
     PubMed    
     
     
     
557. LIAW YF, Jeng WJ, Chien RN
     Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
     Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641.
     PubMed    
     
     
     
558. 
     Erratum: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
     Hepatology. 2023 Oct 16. doi: 10.1097/HEP.0000000000000621.
     PubMed    
     
     
     
559. VONADA A, Wakefield L, Martinez M, Harding CO, et al
     Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation.
     Hepatology. 2023 Oct 12. doi: 10.1097/HEP.0000000000000631.
     PubMed     Abstract available
     
     
     
560. CHEN P, Dong Z, Zhu W, Chen J, et al
     Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for hepatocellular carcinoma.
     Hepatology. 2023 Oct 11. doi: 10.1097/HEP.0000000000000623.
     PubMed     Abstract available
     
     
     
561. MA S, Chew V
     Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
     Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000626.
     PubMed    
     
     
     
562. THIELE M, Johansen S, Israelsen M, Trebicka J, et al
     Non-invasive assessment of hepatic decompensation.
     Hepatology. 2023 Oct 6. doi: 10.1097/HEP.0000000000000618.
     PubMed     Abstract available
     
     
     
563. PENNISI G, Enea M, Romero-Gomez M, Bugianesi E, et al
     Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.
     Hepatology. 2023 Oct 2. doi: 10.1097/HEP.0000000000000616.
     PubMed     Abstract available
     
     
     
564. XANTHAKOS S
     Rising tide of NAFLD in youth: A warning bell and call to action.
     Hepatology. 2023;78:1017-1019.
     PubMed    
     
     
     
565. ANTON A, Shalaby S, Hernandez-Gea V
     Coagulation meets senescence in NASH!
     Hepatology. 2023;78:1023-1025.
     PubMed    
     
     
     
566. YONEDA M, Nakajima A
     The role of MRI technology in liver evaluation for NAFLD patients: Advancements and opportunities.
     Hepatology. 2023;78:1020-1022.
     PubMed    
     
     
     
567. CHEN W, Sun Y, Chen S, Ge X, et al
     Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities.
     Hepatology. 2023;78:1118-1132.
     PubMed     Abstract available
     
     
     
568. LI J, Lu X, Zhu Z, Kalutkiewicz KJ, et al
     Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH.
     Hepatology. 2023;78:1200-1208.
     PubMed     Abstract available
     
     
     
569. KIM ??? WR, Iwakiri ???? Y, Lok ??? ASF
     What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west.
     Hepatology. 2023;78:1032-1034.
     PubMed    
     
     
     
570. MINCIUNA I, Gallage S, Heikenwalder M, Zelber-Sagi S, et al
     Intermittent fasting-the future treatment in NASH patients?
     Hepatology. 2023;78:1290-1305.
     PubMed     Abstract available
     
     
     
571. CALZADILLA-BERTOT L, Jeffrey GP, Wang Z, Huang Y, et al
     Predicting liver-related events in NAFLD: A predictive model.
     Hepatology. 2023;78:1240-1251.
     PubMed     Abstract available
     
     
     
572. SEIMIYA T, Otsuka M, Fujishiro M
     Overcoming T-cell exhaustion: New therapeutic targets in HCC immunotherapy.
     Hepatology. 2023;78:1009-1011.
     PubMed    
     
     
     
573. 
     Erratum: Down-Regulation of the Cyclin-Dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
     Hepatology. 2023;78:E85.
     PubMed    
     
     
     
574. STRAVITZ RT, Fontana RJ, Karvellas C, Durkalski V, et al
     Future directions in acute liver failure.
     Hepatology. 2023;78:1266-1289.
     PubMed     Abstract available
     
     
     
575. HARTMANN P, Zhang X, Loomba R, Schnabl B, et al
     Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019.
     Hepatology. 2023;78:1168-1181.
     PubMed     Abstract available
     
     
     
576. KOTULKAR M, Paine-Cabrera D, Abernathy S, Robarts DR, et al
     Role of HNF4alpha-cMyc interaction in liver regeneration and recovery after acetaminophen-induced acute liver injury.
     Hepatology. 2023;78:1106-1117.
     PubMed     Abstract available
     
     
     
577. DE ANGELIS RIGOTTI F, Wiedmann L, Hubert MO, Vacca M, et al
     Semaphorin 3C exacerbates liver fibrosis.
     Hepatology. 2023;78:1092-1105.
     PubMed     Abstract available
     
     
     September 2023
578. NAHON P, Layese R, Ganne-Carrie N, Moins C, et al
     The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis.
     Hepatology. 2023 Sep 29. doi: 10.1097/HEP.0000000000000615.
     PubMed     Abstract available
     
     
     
579. LI M, Wang L, Cong L, Wong CC, et al
     Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
     Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000591.
     PubMed     Abstract available
     
     
     
580. RINELLA ME, Lieu HD, Kowdley KV, Goodman ZD, et al
     A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis.
     Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000607.
     PubMed     Abstract available
     
     
     
581. ZHAO X, Kotha S, Nayyar D, Ma X, et al
     Physiologic changes in the hepatopulmonary syndrome before and after liver transplant: A longitudinal and predictor analysis.
     Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000605.
     PubMed     Abstract available
     
     
     
582. FAILLI M, Demir S, Del Rio-Alvarez A, Carrillo-Reixach J, et al
     Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response.
     Hepatology. 2023 Sep 20. doi: 10.1097/HEP.0000000000000601.
     PubMed     Abstract available
     
     
     
583. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
     Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
     PubMed     Abstract available
     
     
     
584. WATT KD, Paul S, Khan MQ, Siddiqui M, et al
     Obesity management for the hepatologist - what to do, how to do it and why.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000598.
     PubMed     Abstract available
     
     
     
585. CHEN S, Liao C, Hu H, Liao J, et al
     Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous hepatocellular carcinoma.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000599.
     PubMed     Abstract available
     
     
     
586. MAESTRI E, Kedei N, Khatib S, Forgues M, et al
     Spatial proximity of Tumor-Immune interactions predicts patient outcome in hepatocellular carcinoma.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000600.
     PubMed     Abstract available
     
     
     
587. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
     Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
     PubMed     Abstract available
     
     
     
588. 
     December 2023 Hepatology Highlights.
     Hepatology. 2023 Sep 14. doi: 10.1097/HEP.0000000000000594.
     PubMed    
     
     
     
589. WU T, Chen X, Xu K, Dai C, et al
     LIM domain only 7 negatively controls non-alcoholic steatohepatitis in the setting of hyperlipidaemia.
     Hepatology. 2023 Sep 1. doi: 10.1097/HEP.0000000000000585.
     PubMed     Abstract available
     
     
     August 2023
590. GE J, Fontil V, Ackerman S, Pletcher MJ, et al
     Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis.
     Hepatology. 2023 Aug 23. doi: 10.1097/HEP.0000000000000583.
     PubMed     Abstract available
     
     
     
591. PEISELER M, Tacke F
     Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
     Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
     PubMed    
     
     
     
592. BOWLUS CL, Levy C
     Optimizing treatment of primary biliary cholangitis: Is good, good enough?
     Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
     PubMed    
     
     
     
593. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
     Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
     Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
     PubMed     Abstract available
     
     
     
594. 
     August Hepatology Highlights.
     Hepatology. 2023;78:369-370.
     PubMed    
     
     
     July 2023
595. 
     July 2023 Hepatology Highlights.
     Hepatology. 2023;78:1-2.
     PubMed    
     
     
     June 2023
596. SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
     Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
     Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
     PubMed     Abstract available
     
     
     May 2023
597. 
     May 2023 Hepatology Highlights.
     Hepatology. 2023;77:1461-1462.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.